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ABSTRACT

Anemia adversely impacts the health of more than a billion people worldwide. A
strong association between anemia and arsenic exposure has been reported in
epidemiological studies from multiple countries. However, the mechanistic bases for the
association between arsenic exposure and anemia is not fully understood. In this study,
we found an inverse association between drinking water arsenic exposures and clinical
indicators of anemia (i.e., red blood cell counts and hematocrit/packet cell volumes) in a
cohort of men from rural Bangladesh enrolled in the Health Effects of Arsenic
Longitudinal Study.
Follow-up studies in mice, revealed that 60-day exposure to trivalent inorganic
arsenic (arsenite, As+3) via drinking water resulted in anemia due to the impaired
development of early erythroid progenitor cells in the bone marrow. To gain an
understanding of the mechanisms of As+3-induced suppression of erythroid progenitor
cell development, we utilized an in vitro model of erythropoiesis using primary mouse
bone marrow hematopoietic progenitor cells. As+3 and the As+3 metabolite,
vi

monomethyarsonous acid (MMA+3) suppressed erythropoiesis in the bone marrow,
beginning at very early stages of erythroid differentiation. We found that As+3 selectively
disrupted the function of an essential transcriptional regulator of erythropoiesis, GATA-1.
Impairment of GATA-1 resulted from As+3 interaction with the zinc finger motifs of
GATA-1, causing an inhibition of erythropoiesis and an imbalance of hematopoietic
differentiation.
MMA+3 was also found to impair the differentiation of early erythroid progenitors
through the loss of GATA-1 and by the suppression of erythropoietin (EPO)-activated
signal transducer and activator of transcription 5 (STAT5) signaling. Disruption of
GATA-1 and GATA-1/EPO-activated STAT5 by As+3 and MMA+3, respectively
compromised the regulation of a critical prosurvival factor, B-cell lymphoma-extra-large,
resulting in the aberrant cell death of early erythroid progenitor cells.
Results from this study clearly demonstrate that early developing erythroid
progenitors in the bone marrow are sensitive targets of As+3 and MMA+3 toxicity.
MMA+3 was found to be more toxic than As+3 to early erythroid progenitor cells, likely
by disrupting multiple pathways necessary for erythropoiesis. For the first time, this study
provides novel mechanistic information of arsenic-induced dysregulation and inhibition
of erythropoiesis, which is potentially a significant contributing factor to the high
incidence of anemia in people chronically exposed to arsenic.
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CHAPTER 1

GENERAL INTRODUCTION

1

GENERAL INTRODUCTION

Arsenic Exposure and Toxicological Implications of Arsenic Metabolism
Arsenic is a pervasive environmental toxicant and common contaminant in soil,
air, food, and water (Hughes 2011; WHO 2011). Chronic arsenic exposure is associated
with numerous cancers and diseases, stemming from toxicity to nearly every major organ
and organ system in the body, including the skin, liver, kidneys, bladder, cardiovascular
system, respiratory system, nervous system, endocrine system, and immune system
(Hughes et al., 2002; Heck et al., 2008; Naujokas et al., 2013; Tyler and Allan 2014;
Ferrario et al., 2016).
A major route of human exposure to arsenic is through the consumption of
contaminated drinking water (ASTDR 2007, 2016; WHO 2011). Millions of people
worldwide are chronically exposed to arsenic in their drinking water at levels that exceed
the World Health Organization and United States Environmental Protection Agency
maximum contaminant level of 10 ppb (ATSDR 2007, 2016; U.S. EPA 2012; WHO
2011). Arsenic contamination of groundwater, which is the primary source of drinking
water in many countries, results from natural geological sources as well as anthropogenic
activities (Focazio et al., 1999; WHO 2011; Herath et al., 2016). In drinking water,
arsenic is found primarily in the inorganic forms of arsenate (As+5) and arsenite (As+3)
(ATSDR 2007, 2016).
As+3 is the most toxic inorganic arsenical (Styblo et al., 2000), and once ingested,
is metabolized in the liver, kidneys, lungs, and testes through a series of reduction and
oxidative methylation reactions catalyzed by the arsenite (+3 oxidation state)
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methyltransferase (As3MT) enzyme to monomethylarsonic acid (MMA+5),
monomethylarsonous acid (MMA+3), dimethylarsinic acid (DMA+5), and
dimethylarsinous acid (DMA+3) (Thomas et al., 2001; Vahter, 2002). The in vivo
metabolism of arsenic is depicted in Figure 1.1.
Arsenic metabolism has an important role in detoxification, but also generates
bioactive intermediates with greater toxicity than the parent inorganic arsenicals (Vahter
2002; Douillet et al., 2017). Multiple in vitro and in vivo studies have found MMA+3 and
DMA+3 to be more toxic than As+5 and As+3 (Petrick et al., 2000; Petrick et al., 2001;
Thomas et al., 2001; Stýblo et al., 2002). Additional studies also indicate that MMA+5
and DMA+5 are less toxic than As+3 and MMA+3 (Vahter and Concha 2001; Stýblo et al.,
2002; Gusman et al., 2013). The predominant forms of arsenic most readily excreted in
urine are MMA+5 and DMA+5 (Vahter 2002).
The biotransformation of arsenic is contingent on the activity of As3MT (Lin et
al., 2001; Thomas et al., 2007). Variations in the As3mt gene produced by single
nucleotide polymorphisms result in interindividual differences in arsenic metabolism and
are associated with differential sensitivities to arsenic toxicity (Vahter et al., 1995; Vahter
1999a; Engström et al., 2010). Epidemiological studies in populations chronically
exposed to arsenic have shown that arsenic methylation capacity is associated with
elevated cancer incidence and disease risk (Yu et al., 2000; Chen et al., 2003, 2009;
Ahsan et al., 2007; Huang et al., 2008; Lin et al., 2018; Luo et al., 2018). The proportions
of excreted arsenic metabolites are indicative of arsenic methylation efficiency (Vahter
1999a,b; Gamble et al., 2005). Higher levels of DMA+5 relative to MMA+5 in urine is
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indicative of more efficient arsenic metabolism and is associated with decreased toxicity
(Vahter and Concha 2001; Vahter 2002).
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Figure 1.1. Biotransformation of arsenic in mammals. Arsenic (in the form of As+5 or
As+3) is metabolized in vivo through a series of reduction and oxidative methylation
reactions catalyzed by As3MT using glutathione (GSH) as a reducing agent and Sadenosylmethionine (SAM) as a methyl donor (Gamble et al., 2005). As+3 is converted to
di- and mono-methyl intermediates that are readily excreted from the body (MMA+5 and
DMA+5) and that have greater toxicity (MMA+3 and DMA+3) than the inorganic
arsenicals, As+5 and As+3 (Thomas et al., 2001; Vahter 2002; Stýblo et al., 2002).
Glutathione disulfide (GSSG); S-adenosylhomocysteine (SAH)
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Epidemiological Evidence of Arsenic-Associated Anemia
Anemia is a hematological disorder that negatively affects the health of more than
a billion people worldwide (Koury 2014; Kassebaum et al., 2014; WHO 2015). Anemia
is caused by insufficient quantities of circulating red blood cells (RBCs) and/or by
reduced hemoglobin levels in circulating RBCs (Kassebaum et al., 2014; WHO 2015).
Many deleterious health effects are associated with anemia, including fatigue, increased
susceptibility to infection, cognitive and motor impairments, heart failure, pre-term birth,
low birth weights, and risk of maternal and neonatal mortality (Balarajan et al., 2011;
WHO 2015; Kassebaum et al., 2014).
The prevalence of anemia is disproportionately high in regions with high endemic
arsenic exposures, even after consideration of important confounding risk factors of
anemia (e.g., iron deficiency) (Kile et al., 2016). Epidemiological reports from these
regions indicate a strong relationship between arsenic exposure and anemia (Brenton et
al., 2006; Hopenhayn et al., 2006; Heck et al., 2008; Majumdor et al., 2009; Surdu et al.,
2015; Kile et al., 2016). A summary of these studies and their major findings is provided
in Table 1.1.
The frequency of arsenic-associated anemia is high among women, particularly
during pregnancy (Hopenhayn et al., 2006; Surdu et al., 2015). Surdu et al., (2015),
showed that low-level arsenic exposure (<10 ppb) was associated with an increased
prevalence of anemia among pregnant women. Moreover, Hopenhayn et al., (2006),
reported that not only was drinking water arsenic-exposure (33-53 ppb) associated with
anemia during pregnancy, but the risk of anemia was exacerbated as pregnancy
progressed, with 49% of arsenic exposed women being anemic in the third trimester
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compared to 17% in an unexposed (<1 ppb) population. Arsenic-associated anemia in
men has not been as thoroughly investigated as in females; however, all three studies
which included men also found associations between arsenic exposure and anemia
(Breton et al., 2006; Heck et al., 2008; Majumdor et al., 2009). Despite the strong
epidemiological evidence of arsenic-associated anemias, the mechanistic bases for these
associations remains to be elucidated.
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Table 1.1. Epidemiological evidence of arsenic-associated anemia.
Exposure

Country

Cohort

Effects

Reference

Drinking Water
(median 39 ppb)

Bangladesh

900 men

Arsenic exposed participants more likely to be
anemic than controls (13.5% vs. 10.5 %), and
arsenic exposed women more likely than men
(18.2% vs. 8.2%) to be anemic.

Brenton et al., 2006

and women

Odds of arsenic skin lesions inversely
associated with hemoglobin in males, but not
females.
Chile

Urinary arsenic
(>200 ppb)

Bangladesh

Drinking water
(>800 ppb)

India

Drinking water
(<10 ppb)

Romania

Drinking water

Bangladesh

(median 17 ppb)

810
pregnant

Arsenic exposed women more likely to be
anemic during pregnancy.

women

Anemia prevalence among arsenic exposed
women increased as pregnancy progressed
(49% vs. 17%).

1954 men
and women
7683 men
and women

Inverse association between arsenic exposure
and hemoglobin in men and women with
hemoglobin <12 g/dL.
Increased frequency of anemia in arsenic
exposed men and women.

217 women Increased prevalence of anemia among arsenic
exposed women, particularly during pregnancy.
147 women Higher risk of developing arsenic-caused skin
lesions in anemic women.
Anemia in 75% of participants was not caused
by iron deficiency.

Hopenhayn et al., 2006
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Drinking water
(33-53 ppb)

Heck et al., 2008

Majumdor et al., 2009
Surdu et al., 2015
Kile et al., 2016

Hematopoiesis
The mammalian hematopoietic system is responsible for producing staggering
numbers of blood cells consistently throughout life (Orkin and Zon 2008; Rieger and
Schroeder 2012; Jagannathan-Bogdon and Zon 2013). Hematopoiesis is the process by
which multipotent hematopoietic stem cells (HSCs) give rise to all major cell lineages of
the blood, including lymphocytes, myeloid cells, monocytes, megakaryocytes, and RBCs
(Figure 1.2.) (Metcalf 2007; Rieger and Schroeder 2012). In adult humans and rodents,
the primary site of hematopoiesis is the bone marrow (Rieger and Schroeder 2012;
Jagannathan-Bogdon and Zon 2013). Although HSCs are very rare among the total bone
marrow cell population (approximately 0.06%), they are responsible for generating an
enormous amount of lineage specialized cells on a daily basis (Rieger and Schroeder
2012).
The developmental fate of HSCs relies on extrinsic and intrinsic regulation for
commitment and subsequent development of lineage specific cell types (Orkin and Zon
2008; Rieger and Schroeder 2012). Extrinsic regulation of HSC lineage commitment is
dictated by a number of different cytokines and hormones, including interleukin (IL)-3,
IL-6, IL-7, stem cell factor (SCF), erythropoietin (EPO), granulocyte-macrophage-colony
stimulating factor, macrophage-colony stimulating factor, glucocorticoids, etc., (Rieger
and Schroeder 2012). The presence or absence of these stimuli act as a mechanism by
which the bone marrow microenvironment influences the differentiation fate of HSCs
(Rieger and Schroeder 2012).
Additionally, a number of intrinsic regulatory factors, including transcription
factors, signaling modulators, epigenetic modifiers, cell cycle regulators, microRNAs,
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and RNA binding proteins have a critical role in regulating the differentiation of HSCs
(Orkin and Zon 2008; Rieger and Schroeder 2012). Interplay between extrinsic and
intrinsic regulators, combined with the plasticity of HSCs, provides the foundation of the
mammalian blood system (Graf 2002; Rieger and Schroeder 2012).
One path of HSC lineage differentiation is commitment to multipotent common
myeloid progenitors (CMPs), which give rise to myeloid cells, monocytes,
megakaryocytes, and RBCs (Metcalf 2007; Seita and Weissman 2010; Rieger and
Schroeder 2012). The lineage commitment choices of CMPs is under debate; however,
the current hypothesis is that the fate of these cells is intrinsically regulated through the
expression and subsequent functional antagonism of two major transcriptional regulators
of erythro-megakaryopoiesis and myelopoiesis, GATA-1 and PU.1, respectively (Zhang
et al., 1996; Rekhtman et al., 1999; Nerlov et al., 2000).
CMPs express low levels of GATA-1 and PU.1, but in response to stimulation
from the bone marrow microenvironment, GATA-1 or PU.1 reach a threshold expression
level and work reciprocally to interfere with the activity of the other transcription factor
(Iwasaki and Akashi 2007). GATA-1 binds directly to PU.1 to impair its function,
thereby reducing the expression of myeloid-specific genes (Nerlov et al., 2000;
Rekhtman et al., 1999; Rhodes et al., 2005). In contrast, PU.1 binds to GATA-1 DNA
binding sites, thereby reducing its ability to activate erythro-megakaryocytic-specific
gene transcription (Zhang et al., 1996; Rekhtman et al., 1999).
As result of GATA-1 antagonism of PU.1, CMPs are pushed to the erythromegakaryocytic lineage and undergo subsequent erythroid and megakaryocyte
differentiation (Nerlov et al., 2000; Rekhtman et al., 1999; Rhodes et al., 2005). This
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mechanism of functional interference acts as a regulatory control for dictating the lineage
commitment of CMPs (Iwasaki and Akashi 2007). Once committed to erythromegakaryocytic differentiation, CMPs further mature to megakaryocyte-erythroid
progenitors (MEPs) (Iwasaki and Akashi 2007). In response to extrinsic and intrinsic
regulation, MEPs undergo additional stages of differentiation to produce megakaryocytes
and mature RBCs (Orkin and Zon 2008).

11

Figure 1.2. Hematopoietic hierarchy. Representation of the lineage commitment and
differentiation of HSCs. In response intrinsic (pictured) and extrinsic stimuli, HSCs and
downstream multipotent progenitors give rise to the major functionally specialized cell
types of the blood (RBCs, megakaryocytes, myeloid and monocytes, and lymphocytes)
(Orkin and Zon 2008). Reprinted from Cell, 132(4), Orkin and Zon, Hematopoiesis: An
Evolving Paradigm for Stem Cell Biology, 631-644, Copyright 2008, with permission
from Elsevier Inc.
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Red Blood Cell Development
In adult humans, more than 2 million RBCs are produced every second and
approximately 2×1011 every day to maintain normal physiological circulating levels
(Dzierzak and Philipsen 2013; Kim et al., 2015a). The bone marrow is the primary site of
RBC development (i.e., erythropoiesis) in adult humans and rodents (Tsiftsoglou et al.,
2009; Dzierzak and Philipsen, 2013). However, in mice the spleen also has a critical
function as an erythropoietic organ, especially if the bone marrow system is
compromised (Dzierzak and Philipsen 2013). The stages and factors required for
erythroid differentiation are largely conserved between humans and mice (Pishesha et al.,
2014). The stages of erythropoiesis are depicted in Figure 1.3.
Erythropoiesis is controlled predominately by the hormone, erythropoietin (EPO),
which is released from the kidneys in response to hypoxic conditions in the body
(Hattangadi et al., 2011). EPO acts on early erythroid progenitor cells to promote
survival, proliferation, and differentiation (Koury and Bondurant 1990; Hattangadi et al.,
2011; Bunn 2013). The first detectable stage of committed erythroid differentiation is the
slow proliferating, burst-forming unit erythroid cells (BFU-E), which were originally
identified based on characteristic burst morphology colonies formed in methylcellulosebased medium (reviewed in Dzierzak and Philipsen 2013). BFU-E respond to elevated
EPO along with other growth factors (glucocorticoids, SCF, IL-3, IL-6, etc.,) to mature to
the highly proliferative and EPO-dependent, colony-forming unit erythroid cells (CFU-E)
(Hattangadi et al., 2011; Dzierzak and Philipsen 2013).
CFU-Es were originally identified based on their ability to rapidly form colonies
in methylcellulose-based medium (Dzierzak and Philipsen 2013). At the CFU-E stage,
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hemoglobin production is initiated, and the cells undergo four additional stages of
differentiation to proerythroblast, basophilic erythroblast, polychromatophilic
erythroblast, and orthochromatophilic erythroblast (Migliaccio, 2010; Elliott and Sinclair,
2012).
During the latter four stages of differentiation (i.e., proerythroblast, basophilc,
polychromatophilic, and orthochromatophilic), erythroid progenitors undergo a series of
morphological and biochemical changes, such as size reduction, nuclear condensation,
hemoglobin accumulation, and reduced proliferative capacity (Palis 2014; Moras et al.
2017). Following the orthrochromatophilic erythroblast stage, the nucleus is extruded
forming short-lived pyrenocytes, and reticulocytes that are released from the bone
marrow into circulation (Palis 2014).
Newly formed reticulocytes complete maturation in circulation (~1 week) by
further reducing plasma membrane surface area and cell volume, clearing remaining
organelles, and increasing cytoskeletal interactions with the outer plasma membrane,
resulting in mature RBCs with characteristic biconcave morphology (Griffiths et al.,
2012; Palis 2014). Mature RBCs have a circulating half-life of approximately 120 days in
humans and 45 days in mice (Dzierzak and Philipsen 2013; Palis 2014); i.e., after 120
days in humans (or 45 days in mice) the total circulating red blood cell pool will be
entirely replenished by newly produced cells.
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Figure 1.3. Stages of bone marrow erythropoiesis. In response to GATA-1, CMPs
commit to the erythro-megakaryocytic lineage and differentiate to pre-megakaryocyte
erythroid progenitors (Pre-MegE) (Iwasaki and Akashi 2007). Pre-MegE differentiate to
MEPs, which give rise to RBCs and megakaryocytes (Pronk et al., 2007). The first
identifiable stage of erythroid differentiation is BFU-E, which respond to increased EPO
and other growth factors to mature to the EPO dependent CFU-E stage (Dzierzak and
Philipsen 2013). CFU-E undergo additional stages of differentiation (i.e., proerythroblast
(ProE); EryA, basophilicerythroblast; EryB, polychromatophilic erythroblast; and EryC,
orthochromatophilic erythroblast), prior to enucleation and release from bone marrow
into the circulation as a reticulocyte (Retic.) (Migliaccio, 2010; Elliott and Sinclair,
2012). Reticulocytes complete their development in circulation to become mature RBCs
(Palis 2014).

15

Regulation of Erythropoiesis: GATA-1 and Erythropoietin Signaling
Erythropoiesis is an intricate process that relies on extrinsic and intrinsic
regulation by many factors (e.g., hormones, cytokines, signal transduction pathways, cell
cycle modulators, transcription factors, regulatory RNAs, epigenetic modifications, etc.,)
for normal differentiation of erythroid progenitor cells (Hattangadi et al., 2011; Dzierzak
and Philipsen, 2013). The development of early erythroid progenitors is dependent on the
activities of two critical regulatory pathways mediated by GATA-1 and EPO signaling
(Ferreira et al., 2005; Dzierzak and Philipsen, 2013).
GATA-1 is a zinc finger transcription factor that is regarded as the master
regulator of erythropoiesis (Ferreira et al., 2005). GATA-1 is responsible for inducing
and repressing many genes essential for erythroid differentiation and also has a critical
role in the regulation of hemoglobin production (Evans et al., 1988; Pevny et al., 1991;
Pevny et al., 1995; Welch et al., 2004; Ferreira et al., 2005; Katsumuara et al., 2013).
GATA-1 expression levels vary throughout the stages of erythropoiesis, but the activity
of this key transcription factor peaks at the late BFU-E and CFU-E stages of
differentiation (Ferreira et al., 2005).
GATA-1 knockout studies revealed the necessity of this factor for erythropoiesis,
as GATA-1 null embryos die from severe anemia, resulting from arrested differentiation
and apoptosis of early stage erythroid progenitors (Weiss et al., 1994; Weiss and Orkin
1995; Pevny et al., 1995; Fujiwara et al., 1996). GATA-1 knockdown studies further
confirmed the dependence of early erythroid progenitors on the activity of GATA-1,
showing that graded loss of GATA-1 (i.e., 5 to 20% of normal GATA-1 levels) results in
an expression-level dependent impairment of erythropoiesis (McDevitt et al., 1997).
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Another critical regulatory mechanism in early erythroid cells is the EPOactivated signal transducer and activator of transcription 5 (STAT5) prosurvival pathway
(Socolovsky et al., 1999; 2001; Liu et al., 2006). Expression of the EPO receptor is
mediated by GATA-1 in early erythroid progenitors (Zon et al., 1991; Ferreira et al.,
2005). The EPO receptor is a member of the type 1 cytokine receptor superfamily
(Watowich 2011). EPO binding to the EPO receptor induces the dimerization and
phosphorylation of tyrosine residues in the intracellular domain by Janus kinase 2
(JAK2), which is constitutively associated with the cytoplasmic domain of the EPO
receptor (Watowich 2011).
EPO receptor phosphorylation provides docking sites for signaling molecules
including, STAT5 (Watowich 2011). There are two isoforms of STAT5, STAT5a and
STAT5b, which share 95% amino acid sequence identity (Liu et al., 1995). STAT5
recruitment and phosphorylation by the EPO receptor/JAK2 complex is essential for
mediating downstream EPO-activated signaling events (Watowich 2011). Activated
STAT5 is an essential regulatory factor that mediates signaling events critical for the
survival, proliferation, and differentiation of early erythroid progenitor cells (Socolovsky
et al., 1999; 2001; Watowich 2011).
Similar to GATA-1, EPO responsiveness also peaks at the late BFU-E and CFU-E
stages of erythroid differentiation (Wu et al., 1995; Ferreira et al., 2005). EPO
deprivation studies in erythroid progenitor cell models and STAT5 knockout studies in
mice show that loss of STAT5 causes an inhibition of erythropoiesis by the loss of B-cell
lymphoma-extra-large (Bcl-xL) regulated survival of early erythroid progenitors and
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results in severe anemia (Gregory et al., 1999; Silva et al., 1996; Socolovsky et al., 1999,
2001).
Follow-up studies demonstrate a role for GATA-1 in this EPO-activated STAT5
prosurvival pathway (Gregory et al., 1999). GATA-1 and EPO-activated STAT5
cooperate to promote optimal expression of the prosurvival factor Bcl-xL, thereby
preventing apoptosis of early erythroid progenitor cells (Figure 1.4) (Gregory et al.,
1999). Under steady-state EPO conditions, most early erythroid progenitors (~60%)
succumb to apoptosis via this mechanism; however, with elevated EPO levels, such as
experienced with hypoxia, this mechanism promotes the survival and rapid expansion of
early erythroid progenitors (Dzierzak and Philipsen, 2013).
This prosurvival mechanism controls erythropoietic rate and provides the basis for
the plasticity of the bone marrow erythropoietic system, as it directly links EPO levels to
the survival and differentiation of erythroid progenitors (Koulnis et al., 2012). It is
important to note, that loss of either GATA-1 or EPO-activated STAT5 is sufficient to
induce apoptosis and reduce the maturation of erythroid progenitors (Weiss and Orkin
1995; Socolovsky et al., 2001). Considering the importance of GATA-1 and STAT5 for
the survival and differentiation of early erythroid progenitors, disruption of these
pathways by arsenic may be a mechanism of arsenic-induced hematotoxicity.
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Figure 1.4. Schematic diagram of GATA-1 and EPO-activated STAT5 prosurvival
pathway in early erythroid progenitors (late-BFU-E cells, CFU-E cells, and ProEs)
(Gregory et al., 1999). GATA-1 and EPO-activated STAT5 cooperate to stimulate the
optimal expression of the prosurvival factor B-cell lymphoma-extra-large (Bcl-xL), which
functions to prevent caspase-3 mediated death of early erythroid progenitors (Gregory et
al., 1999).
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Evidence of Arsenic-Induced Hematotoxicity
Despite the direct link between decreased RBC production and anemia (Koury
2014), the effects of arsenic on erythropoiesis have not been thoroughly investigated.
Several studies report arsenic toxicity to mature circulating RBCs. Arsenic exposure
causes oxidative stress, depletes intracellular ATP, and alters morphological
characteristics of mature RBCs, resulting in compromised membrane integrity, eryptosis,
and intra-and-extravascular hemolysis (Winski et al., 1997; Winski and Carter, 1998;
Zhang et al., 2000; Biswas et al., 2008; Mahmud et al., 2009).
To date, very few studies have been performed to evaluate the effects of
environmentally relevant arsenic exposures on early erythroid progenitor cells in the bone
marrow. Acute exposure to high levels of arsenic has been reported to cause anemia in
humans and rodents as a result of bone marrow depression (Szymańska-Chabowska et al.,
2002), suggesting that the development of RBCs may be a target of arsenic toxicity.
Studies focused on the chemotherapeutic actions of arsenic trioxide in erythroleukemia
cell line models have also provided some evidence of arsenic toxicity to RBCs (Saulle et
al., 2006; You et al., 2005). Despite the limitations of using erythroleukemia cells as
models of normal erythroid cell biology, findings from these studies suggest that arsenic
disrupts pathways important for differentiation and survival of erythroid cells.
Toxicological investigations of hematopoietic progenitors following
environmentally relevant metal exposures are limited, likely resulting from the difficulty
of studying these rare cell types. Ferrario et al., (2008), found that the development of
myeloid progenitors (CFU-GM) was suppressed by in vitro As+3 and MMA+3 exposures.
Additionally, previous studies from our lab showed that the development of pre-B cells in
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the bone marrow and pre-T cells in the thymus is suppressed by low levels of As+3 and
MMA+3 (Ezeh et al., 2014; Xu et al., 2016a; Xu et al., 2017). These studies show that
hematopoietic progenitors in the bone marrow are sensitive to arsenic-induced toxicity
and highlight the necessity for further investigations to understand the effects of
environmental metal exposures on these vulnerable cell populations.
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GATA-1 and Erythropoietin-Activated STAT5 as Targets of Arsenic Toxicity
Regulation of erythropoiesis is dependent on two critical pathways mediated by
the activity of GATA-1 and STAT5. Interestingly, zinc finger proteins (such as GATA-1)
and STAT5 signaling are known targets of arsenic toxicity (Cheng et al., 2004a; Wetzler
et al., 2006; Ding et al., 2009; Zhou et al., 2011; Sun et al., 2014; Zhou et al., 2015; Ezeh
et al., 2016a, Xu et al., 2016a). GATA-1 contains two C4 zinc fingers, one in the Nterminal domain and one in the C-terminal domain (Ferreira et al., 2005). The N-terminal
zinc finger of GATA-1 is essential for protein-protein interactions and the C-terminal
zinc finger is necessary for DNA binding (Fox et al., 1999; Liew et al., 2005; Bates et al.,
2008). Congenital mutations in the N- or C-terminal zinc finger motifs of GATA-1 result
in dyserythropoietic anemia (Del Vecchio et al., 2005; Ciovacco et al., 2008; Crispino
and Horwitz 2017).
As+3 and MMA+3 are documented to inhibit the function of zinc finger proteins by
displacing zinc from zinc finger motifs (Ding et al., 2009; Zhou et al., 2011; Sun et al.,
2014; Zhou et al., 2014). As+3 selectively interacts with C3H1 and C4 zinc fingers;
whereas, MMA+3, is less selective and interacts with C2H2, C3H1, and C4 zinc fingers
(Zhou et al., 2011; Zhou et al., 2014). Selective binding of As+3 to C3H1 and C4 zinc
fingers renders cysteine residues in the zinc finger structure vulnerable to oxidation by
As+3-generated reactive oxygen species (Zhou et al. 2015). This selective cysteine thiol
oxidation results in zinc loss and inhibits the function of zinc finger proteins (Zhou et al.
2015).
GATA-1 contains two zinc finger motifs that are structurally favorable for As+3
and MMA+3 binding (Pia̧tek et al., 2008; Zhou et al., 2011; Zhao et al., 2012; Zhou et al.,
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2014). As such, it is likely that As+3 and MMA+3-induced disruption of the zinc finger
motifs of GATA-1 may be an underlying mechanism of toxicity to early developing
erythroid progenitor cells. Additionally, many other transcription factors and
transcriptional coactivators involved in the development of erythroid progenitors are also
zinc fingers with motifs that may be displaced by As+3 and MMA+3 (Hattangadi et al.,
2011).
Since the maturation of erythroid progenitor cells is dependent on STAT5
(Socolovsky et al., 1999; 2001), disruption of EPO-activated STAT5 signaling is another
possible pathway impacted by arsenic exposure. STAT5 activation is also a known target
of arsenic toxicity in progenitor cells (Cheng et al., 2004a; Wetzler et al., 2006; Ezeh et
al., 2016a, Xu et al., 2016a). Previous studies from our lab show that As+3 and MMA+3
inhibit the development of early B cells in the bone marrow and early T cells in the
thymus by reducing IL-7-induced STAT5 activation (Ezeh et al., 2016a; Xu et al.,
2016a). Additionally, studies in cancer cell line models also demonstrate that STAT5
activation is impaired by in vitro exposures to As+3 and arsenic trioxide (ATO) (Cheng et
al., 2004a; Wetzler et al., 2006).
Arsenic trioxide is used as a therapy for treating patients with acute myeloid
leukemia (AML) (Zhang et al., 1996; Shen et al., 1997; Soignet et al., 1998). Constitutive
STAT5 activation is a hallmark of many hematologic cancers, including AML
(Gouilleux-Gruart et al., 1996; Birkenkamp et al., 2001; Benekli et al., 2003). Multiple
studies have demonstrated the utility of ATO-induced JAK2/STAT5 inhibition as an
effective therapeutic intervention for treating AML (reviewed in Benekli et al., 2009).
Arsenic trioxide impairs the phosphorylation of STAT5, thereby reducing cell growth and
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inducing apoptosis of AML cells (Chen et al., 1996; Miller et al., 2002). Similar to ATO,
JAK2/STAT5 inhibitors also show utility as therapeutic agents in the treatment of AML
(Nelson et al., 2011; 2012; Oh et al., 2015; Wingelhofer et al., 2018); however, a major
side effect of the pharmacological inhibition of JAK2/STAT5 is anemia (Harrison et al.,
2012; Verstovsek et al., 2017). These studies not only highlight the utility of STAT5
inhibition as a target for therapeutic intervention in leukemia, but also provide indirect
evidence for the role of STAT5 inhibition in the development of anemia.
To our knowledge, no studies have evaluated arsenic toxicity to early developing
erythroid progenitors. Additionally, a clear mechanistic understanding of arsenicassociated anemia also remains to be elucidated. The goal of this study is to address these
critical knowledge gaps by identifying whether the development of early erythroid
progenitor cells is disrupted by As+3 and MMA+3 exposures and to identify whether such
impairments are mediated through the inhibition of GATA-1 and EPO-activated STAT5
signaling.
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Utilizing an in vitro Model of Erythropoiesis to Characterize Arsenic Toxicity to
Early Erythroid Progenitors
Hematopoietic progenitor cells (HPC), such as erythroid progenitors, occur in
very low abundance among the total bone marrow cell population (Rieger and Schroeder
2012; Dzierzak and Philipsen, 2013). The differentiation of these rare cell populations
has been traditionally studied based on colony-forming ability in cytokine and growth
factor supplemented methylcellulose-based medium (Bradley and Metcalf 1966; Pluznik
and Sachs 1966; Iscove et al., 1974). This method allows for the expansion of a small
number of cells into morphologically identifiable cell colonies. Colony formation is
dependent on differentiation, proliferation, and cell viability; however, deciphering which
of these factors is impacted and at what differentiation stage(s) such alterations occur as
result of toxicant exposure is very difficult. Additionally, colony forming assays are not
readily amendable to mechanistic studies.
To gain a detailed understanding of the effects of arsenic on erythroid progenitor
development, an in vitro model of erythropoiesis was developed using primary mouse
bone marrow HPC stimulated with a combination of EPO and SCF (as described by
Shuga et al., (2007), with some modifications). Advancements in the field of HPC
biology have identified and validated specific cell surface marker phenotypes of all
hematopoietic progenitor lineages (Pronk and Bryder 2011; Grover et al., 2014).
Dynamic changes in surface marker phenotypes can be assessed to monitor the
progression of early HPC through the stages of lineage-specific differentiation using flow
cytometry.
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Stimulation of HPC with EPO and SCF promotes the lineage commitment and
subsequent differentiation of erythroid progenitors. After 24 h of EPO and SCF
stimulation, HPC demonstrate surface marker characteristics of early erythromegakaryocytic and erythroid progenitors (Pre-MegE, MEP, BFU-E, CFU-E,
proerythroblasts). After 48 and 72 h, nearly all major stages of erythroblast differentiation
(e.g., basophilic erythroblasts, late basophilic erythroblasts and polychromatic
erythroblasts, and orthochromatic erythroblasts are identifiable by CD71 and Ter119
surface marker expression and size characteristics (Socolovsky et al., 2001; Koulnis
(2011).
This technique provides a model system to study the developmental progression
of erythroid progenitor cells starting from very early stages of differentiation. This
technique allows us to assess and identify the specific stages of erythroid progenitor
differentiation most impacted by As+3 and MMA+3 exposures. The sensitivity of flow
cytometry, in combination with the minimal cell numbers required for flow cytometry,
allow for the mechanistic assessment of biochemical alterations induced by As+3 and
MMA+3 in surface marker defined early erythroid progenitors.
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HYPOTHESIS AND SPECIFIC AIMS

Overall Hypothesis
Exposure to environmentally relevant concentrations of arsenic impairs
erythropoiesis through the suppression of GATA-1- and STAT5- regulated differentiation
and survival pathways in early erythroid progenitors.

Specific Aims
Specific Aim 1: To evaluate the relationship between arsenic exposure and anemia in
men chronically exposed to As+3, and to determine whether in vivo drinking water
exposures to low levels of As+3 result in the development of anemia in adult mice. Aim 1
is separated into two components, investigating the relationship between chronic arsenic
exposures and anemia in humans (Chapter 1) and mice (Chapter 2). We hypothesize that
hematological indicators of anemia (e.g., RBC counts and hematocrit/packed cell
volumes) will decrease as a function of increasing As+3 exposures in men from rural
Bangladesh. We also hypothesize that exposure of adult male mice to environmentally
relevant levels of As+3 will result in the development of anemia via suppression of early
erythroid progenitor cell development in the bone marrow. This study will reveal whether
arsenic-associated anemia observed in human populations can be recapitulated in a
mouse model and will also provide critical information regarding the in vivo effects of
As+3 on early developing erythroid cells.
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Aim 2: To examine the in vitro effects of As+3 and the As+3 metabolite, MMA+3 on the
erythropoietin (EPO)-induced differentiation of primary mouse bone marrow erythroid
progenitor cells. We hypothesize that As+3 and MMA+3 will suppress the in vitro
differentiation of primary mouse bone marrow erythroid progenitors. This study (Chapter
3 and Chapter 4) will thoroughly characterize the effects of As+3 and MMA+3 on the
differentiation of bone marrow erythroid progenitors, which will reveal the specific
stages of erythroblast development most susceptible to arsenic-induced hematotoxicity.

Aim 3: To characterize the mechanisms responsible for As+3 and MMA+3-induced
suppression of primary mouse bone marrow erythroid progenitor cell development. We
hypothesize that As+3 and MMA+3 suppress the development of early erythroid
progenitors by combined effects on differentiation and survival caused by impairments of
GATA-1 and EPO-activated STAT5 signaling. This aim (Chapter 3 and Chapter 4) will
provide novel mechanistic insights critical for understanding the relationship between
arsenic exposure and anemia reported in epidemiological studies.
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KEY POINTS

•

Arsenic exposure was negatively correlated with clinical indicators of anemia in men.

•

Dose-dependent decreases in RBC and HCT/PCV were found with increasing
drinking water arsenic levels.

•

Correlations between arsenic exposure and clinical indicators of anemia were slightly
stronger among smokers.

•

Relationships between smoking and arsenic exposure suggest potential interactive
effects on clinical indicators of anemia.
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ABSTRACT

Drinking water arsenic (WAs) exposure has been linked to a number of
detrimental health outcomes including anemia, primarily among pregnant women. Little
is known about the effects of arsenic (As) on hematological disorders among men. We
have examined the role of As exposure on hematological indicators of anemia in a group
of men exposed to a wide range of As in their drinking water. We conducted a crosssectional investigation among 119 healthy men in the Health Effects of As Longitudinal
Study (HEALS) cohort, in rural Bangladesh. The participants are part of an ongoing
study focused on evaluating the influence of As and smoking on immune function.
Samples were collected at recruitment and analyzed for water As, urinary As (UAs) and
UAs metabolites to assess As exposure. Blood samples were also collected at recruitment
and assayed immediately for hematological parameters. We found that increased WAs
was associated with decreased red blood cell counts [β= -0.13, p<0.0001] as well as
hematocrit packed cell volume [β= -0.68, p=0.008] following adjustment for age,
smoking, body mass index and polycyclic aromatic hydrocarbon-DNA adducts. Other
measures of As exposure (UAs and its metabolites) demonstrated similar associations.
Slightly stronger effects were observed among smokers. We also observed an effect of As
on hemoglobin among smokers in relation to urinary As [β= -0.54, p<0.05]. Our analysis
revealed effects of As exposure on hematological indicators of anemia in a group of
healthy male smokers and non-smokers.
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INTRODUCTION

As contamination in drinking water is a global public health problem affecting
millions of people worldwide. The major arsenicals found in drinking water are the
pentavalent and trivalent inorganic forms arsenate (As+5) and arsenite (As+3), respectively
(Styblo et al., 2000; Naujokas et al., 2013). As a result, exposure to these inorganic
arsenicals is of particular concern from a public health standpoint (Styblo et al., 2000).
High-level As exposure has been linked with internal and external cancers, lung disease,
immunosuppression, and cognitive impairment in children (Naujokas et al., 2013;
Hughes et al., 2002; Tyler and Allan 2014; Ferrario et al., 2016). A few studies have also
indicated an association between chronic As exposure and hematological disorders such
as anemia, particularly among women during pregnancy (Hopenhayn et al., 2006; Heck
et al., 2008; Surdu et al., 2015; Kile et al., 2016).
Anemia is characterized by reduced red blood cell counts (RBC) and decreased
hemoglobin (Hgb) levels in the blood. Anemia has been linked with a number of
deleterious health effects, including fatigue, increased susceptibility to infection,
cognitive and motor impairments, low birth weights, and risk of maternal and neonatal
mortality (Balarajan et al., 2011; WHO 2011). A cross-sectional study of 217 Romanian
women, found higher prevalence of anemia [prevalence proportion ratio (PPR) =1.71,
95% (CI) 0.75-3.88], and particularly anemia during pregnancy [(PPR)= 2.87, 95% (CI)
0.62-13.26] associated with As exposure (Surdu et al., 2015). Similarly, a follow-up
study of 810 pregnant women from two Chilean cities observed increased incidences of
anemia related to As exposure. This study also revealed increasing prevalence of anemia
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with the progression of pregnancy among As exposed as compared to unexposed women
(49% versus 17%) (Hopenhayn et al., 2006).
We have reported that higher urinary As (>200 µg/L) was linked to low Hgb (<10
g/dL) among 1,954 men and women in the HEALS cohort in Bangladesh (Heck et al.,
2008). Two studies from Bangladesh also reported an association of Hgb on arsenicalinduced skin lesions. In a group of 147 women, Kile et al., (2016) observed that low Hgb
(<12 g/dL) significantly increased risk [(OR) = 3.32, 95% (CI) 1.29, 8.52] of As-related
skin lesions among women with normal Hgb levels after adjusting for As levels in
drinking water and other covariates. Interestingly, the relationship of Hgb and arsenical
skin lesions was found to be gender specific in a case-control study of 900 individuals
from the same area of Bangladesh. Hgb was significantly associated with skin lesions
only among males with a 40% reduction in the odds of skin lesions for every 1 g/dL
increase in Hgb (OR= 0.60; 95% CI, 0.49-0.73). However, no direct associations (n=184)
were observed between toenail As or UAs species and Hgb levels (Breton et al., 2006).
Although a link between smoking and anemia has yet to be established, multiple
diseases caused by smoking can result in anemia (Leifert 2008). Several studies have
found that smoking results in red blood cell hemolysis, which may be a contributing
factor to anemia development (Minamisawa et al., 1990; Masilamani et al., 2016).
Conversely, smoking has also been reported to complicate the identification of anemia by
increasing Hgb and hematocrit packed cell volume (HCT/PCV) (Sagone and Balcerzak
1975; Nordenberg et al., 1990; Anandha, et al., 2014). These studies highlight the
equivocal nature of the relationship between smoking and anemia and emphasize the
need for further investigations.
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There is strong evidence supporting an association between drinking water As
exposure and anemia among women; however, very few studies have evaluated these
relationships in men. To our knowledge, no studies have been conducted to determine the
effects of smoking on anemia in As exposed individuals. Taking this into consideration,
the present study assessed the relationships between chronic drinking water As exposure
and hematological indicators of anemia among healthy male non-smokers and smokers in
the HEALS cohort who live in rural Bangladesh.
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METHODS

Study population
The study was implemented in the HEALS cohort, an ongoing population-based
prospective cohort in Araihazar, Bangladesh, a rural sub-district, near the capital Dhaka
(Parvez et al., 2006). The HEALS cohort was established to investigate the health effects
of inorganic As (InAs) exposure from drinking water (Ahsan et al., 2006; Parvez et al.,
2006). Briefly, between October 2000 and May of 2002 a total of 11,746 married (to
reduce loss to follow-up) men and women were recruited between the ages of 18 to 75
years from a well-defined 25-km2 geographical area where they had been residing for at
least 3 years. The cohort was expanded to include an additional 8,287 participants using
the same methodology between 2006 and 2008. Most recently an additional 15,000
participants were recruited to the HEALS cohort totaling slightly over 35,000 adults.
Participants in the HEALS cohort underwent demographic and lifestyle data collection
using standardized questionnaires. Information on As exposure is assembled by
collecting water and urine samples at multiple time points. A detailed description of the
study cohort has been previously published and described (Ahsan et al., 2006).
Recruitment procedure
We adopted a similar protocol for recruiting study participants based on our past
procedures. The study protocol was approved by the Institutional Review Board of
Columbia University and the Bangladesh Medical Research Council. Informed consent
was obtained from all participants. The study team visited the potential study participants
at their home, explained the study procedure, and ascertained their eligibility criteria
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using a structured questionnaire. A potential list of participants for this study was formed
based on As exposure, age, and smoking status from the HEALS central database. Upon
further examination of the potential participants list a number of participants were
deceased, migrated out of the study area, or had been suffering from a serious illness.
Some eligible participants could not participate because they had taken employment out
of the study area and visit home infrequently only during weekends. A large number of
participants were not eligible to participate because they stopped drinking water from
wells with As concentration (>50 µg/L). Persons identified with illnesses related to
immune function and/or taking any medication that might have an impact on immune
function, including medications for cardiovascular disease or diabetes were not enrolled
in the study. If the participant was eligible, willing, and consented, an appointment was
made for them at the field clinic. Our field team was able to identify 317 eligible
participants to recruit for this study, out of which 267 participants visited our study clinic
and completed the study procedure. We obtained and analyzed hematology and WAs data
from 103 individuals.
Questionnaire data, clinical examination and anthropometric measurement
Following consent to participate in the study, baseline in-person interviews were
performed by trained personnel with detailed questionnaires on lifestyle characteristics.
Participants were asked to provide information on demographics, medical co-morbidities,
and cigarette and betel-nut usage. Questions were also answered on socioeconomic status
defined by television ownership, land ownership, years of education, and occupation.
Anthropometric measurements including height, weight, and blood pressure were
performed using standard techniques.
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Sample collection, processing, and shipment
Information on drinking water was collected at the time of recruitment. If the
study participants used the same water source since 2000 and it had been tested by
Columbia University in the past, then the individuals were consented into the study.
Following consent, trained physicians collected a 20 mL venous blood sample and 40 mL
spot urine sample from each participant.
Blood samples were collected by venipuncture using a vein in the antecubital
fossa into dipotassium EDTA or sodium heparin anticoagulant tubes. Blood samples in
heparinized tubes were processed immediately to isolate peripheral blood mononuclear
cells (PBMC) and blood collected in EDTA tubes was used for hematology. All
hematological parameters were measured immediately at the Araihazar Laboratory,
Columbia University As and Health Research in Bangladesh. All the biological samples
were labeled with machine-readable barcodes to maintain privacy of study participants.
Automated complete blood count (CBC)
A CBC was performed using a MYTHIC 22, a fully automated (Microprocessor
controlled) hematology analyzer used for the in vitro diagnostic testing of whole blood
specimens. MYTHIC 22 is an optical measurement system for analyzing up to 22
hematological parameters.
Water sample collection and measurement of As
Procedures for field sample collection and laboratory analyses are described
elsewhere in detail (Cheng et al., 2004b; Van Geen et al., 2005; Van Geen et al., 2007).
Water samples were analyzed by high-resolution inductively coupled plasma mass
spectrometry (HR ICP-MS) as previously described (Van Geen et al., 2007). The
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analytical detection limit of the method is 0.1 μg/L; the standard deviation of a single
measurement is conservatively estimated at 4 µg/L (Van Geen et al. 2005).
Urine collection, and UAs and creatinine assays
Spot urine samples were collected in 50 mL acid-washed tubes and stored at 80ºC until shipped to Columbia University on dry ice for analysis. UAs assays were
performed with a graphite furnace atomic-absorption (GFAA) instrument using a PerkinElmer Analyst 600 graphite furnace system as described (Nixon et al., 1991). The
detection limit for urinary As was 2 µg/L. Urinary creatinine was analyzed by a
colorimetric method based on the Jaffe reaction.
Urinary As metabolites assay
UAs metabolites were assayed by inductively coupled plasma-mass spectrometry
(ICP-MS-DRC) coupled to high performance liquid chromatography (HPLC). ICP-MSDRC was used as a detector for As metabolites chromatographically separated on an
Anion Exchange Column (Hamilton PRP-X100) with 10 mM ammonium
nitrate/ammonium phosphate, pH 9.1, as the mobile phase (Van Geen et al., 2002). The
excellent separation power of HPLC coupled with the very low detection limits of ICPMS-DRC allowed us to detect InAs (i.e., As+3 and As+5), total monomethylarsonic acid
(MMA), and total dimethylarsinic acid (DMA).
PBMC isolation from peripheral blood
Blood from heparinized tubes was transferred into two 15 mL centrifuge tubes
and was mixed with approximately 14 ml sterile phosphate buffered saline (PBS); 7 mL
of the mixture was layered on top of 4 mL Ficoll-Paque Plus (at room temperature; RT),
a ratio of approximately 2:1 (v/v) and samples were centrifuged at 2700 rpm at RT for 25
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min. Following centrifugation PBMC were collected from the interface of the ficoll. Cells
were diluted with sterile PBS and centrifuged this was repeated two more times. PBMC
were cryopreserved and held in liquid nitrogen until shipped on dry ice to the U.S. for
analysis of PAH-DNA adducts.
Polycyclic aromatic hydrocarbon-DNA (PAH-DNA) adducts
PAH diol epoxide-DNA adducts were analyzed by competitive ELISA, using
methods described previously (Divi et al., 2002). Briefly, 96 microwell plates coated with
2 ng of benzo(a)pyrene diol epoxide (BPDE)-I-DNA (5 adducts/103 nucleotides) and
rabbit antiserum #29 (Poirier 1980) was used with BPDE-DNA as a standard. DNA was
isolated from frozen PBMC samples according to standard procedure using
phenol/chloroform/isoamyl alcohol. DNA was assayed for PAH-DNA adducts after
sonication and denaturation by laboratory technicians blinded to exposure status. For
analytical purposes, those samples with <15% inhibition are considered non-detectable
and assigned a value of 1 adduct /108 nucleotides, an amount midway between the lowest
positive value and zero. A 5% blinded duplication was carried out using those subjects
with the most DNA available. As an additional quality control, a DNA sample from an
animal treated with BP was also assayed was run with the sample batch.
Statistical analysis
Summary statistics were calculated to describe the distribution of all variables for
outliners. Similarly, we used frequency tables, crosstabs, box plots, and scatter plots to
better understand the distribution of the data. T-tests and ANOVA were used to detect
differences in categorical and continuous variables. Water and UAs as well as PAH-DNA
adduct values were log- transformed to normalize their distributions to meet assumptions

39

of ANOVA and reduce the impact of extreme values in linear regression analysis.
Spearman correlation coefficients were used to evaluate bivariate associations among
hematological parameters and the exposure variables. We estimated associations between
As exposure (water, urine and UAs metabolites) and different hematological parameters
in separate linear regression models, with and without adjusting for socio-demographic
characteristics, and other potential confounders (age, body mass index, smoking, length
of education and PBMC PAH-DNA adduct). We repeated the same analysis among
smokers and non-smokers in separate linear regression models adjusting for the same
variables mentioned previously. We also examined interactions between smoking and
PAH-DNA adducts for each measure of hematological parameters by including
multiplicative interaction terms in the models. All statistical analyses were conducted
using Statistical Analysis Software (SAS 9.4) (SAS Institute Inc.).
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RESULTS

Characteristics of the study population
The characteristics of the study population are described in Table 2.1. A majority
of the participants were more than 50 years old (60%) and had a BMI less than 25 (75%).
The majority of participants had at least one or more years of schooling (70%). About
half of the study participants were active smokers (46%) and more than 60% were
exposed to WAs >50 µg/L, a drinking water standard for As in Bangladesh.
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Table 2.1. Sociodemographic, exposure and hematology parameters of the study
participants.a
Sociodemographic
Age
Body Mass Index (BMI)
Education (years)
Exposure history
Water As (µg/L)
Urinary As (µg/g)
Years of well use
Smoking in years
Cigarettes/per day
Packs of cigarettes/per year
PAH-DNA adduct (ng/mL)
Hematology parameters

Mean (range)
52 (36-65)
22.26 (14.50-30.00)
4.50 (0-12)
103.50 (0.10-363.00)
1730.39 (100-11160)
15.12 (3-40)
22.00 (5-30)
18.65 (10-30)
188.62 (0-900)
1.99 (0.90-8.00)

RBC (x106/µL)
HCT/PCV (%)
MCV (fL)
Hgb (g/dL)
WBC (cell/cumm)

4.98 (3.72-.8.98)
42.32 (31.80-70.50)
85.47 (56.50-116.60)
14.03 (10.20-18.20)
9,015.79 (4,20014,700)
34.59 (17.00-57.00)
56.18 (31.00-77.00)
3.78 (1.00-10.00)
5.43 (1.00-13.00)

Lymphocytes (%)
Neutrophils (%)
Monocytes (%)
Eosinophils (%)
a

Red blood cells counts (RBC), hematocrit packed cell volume (HCT/PCV), mean
corpuscular volume (MCV), hemoglobin (Hgb), and total white blood cell counts (WBC).
Data provided as courtesy of Dr. Faruque Parvez.
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Relationships among measures of exposure
The different measures of As exposure (WAs, UAs, and InAs, MMA and DMA)
were moderately correlated with each other (r-values between 0.36 and 0.52 and
p<0.0001, data not shown). However, the correlations among As exposures measures
were relatively stronger among never smokers (r-values between 0.51 and 0.62 and
p<0.0001, data not shown) as compared to smokers. A stronger significant correlation
was observed between WAs and UAs among non-smokers (r= 0.61, p< 0.0001) as
compared to smokers (r= 0.40, p= 0.007). Similar association were observed in relation to
urinary As metabolites. On the other hand, PAH-DNA adducts were correlated only with
WAs (r= 0.40, p<0.001) and did not differ appreciably due to smoking status (data not
shown).
Relationships of As exposure and hematological parameters
In unadjusted models, significant inverse correlations were found between WAs
and RBC and HCT/PCV (Figure 2.1A-B). Furthermore, a dose dependent decrease in
RBC and HCT/PCV was also observed with increasing WAs levels among all
participants (Figure 2.2A-B). Inverse relationships were also found between WAs and
UAs and MCV (ß= 0.38, 95% CI: -0.05, 1.47; p= 0.06) and Hgb (ß= 0.03, 95% CI: -0.10,
0.16; p= 0.66, data not shown). Associations between UAs and RBC and HCT/PCV as
well as other parameters were similar to those observed in relation to WAs (data not
shown). However, a significant inverse correlation was observed between UAs and Hgb
(ß= -0.38, 95% CI: -0.65, -0.12; p= 0.005, data not shown).
Table 2.2 shows associations of As exposure with hematological parameters in
adjusted models. With adjustment for the covariates including age, BMI, educational

43

attainment, smoking, and PAH-DNA adducts, significant inverse associations were
observed between WAs and RBC (ß= -0.13, 95% CI: -0.19, -0.07; p<0.0001) and
HCT/PCV (ß= -0.68, 95% CI: -1.17, -0.19; p= 0.008). The relationship between RBC and
HCT/PCV with UAs was found to be slightly stronger (Table 2.2). Similarly, a strong
positive correlation was observed for total white blood cell counts (WBC) (ß= 516.11,
95% CI: 70.16, 962.06; p= 0.002) in relation to UAs.
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Figure 2.1. Correlations between red blood cell counts (RBC) and hematocrit packed cell
volume (HCT/PCV) with water arsenic concentration in male participants (n=103). A.
Relationship between RBC and water arsenic. B. Association between HCT/PCV and
water arsenic. The red lines indicate 95% confidence intervals. Significance level is
p≤0.05. Data provided as courtesy of Dr. Faruque Parvez.
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Figure 2.2. Changes in red blood cell counts (RBC) and hematocrit packed cell volume
(HCT/PCV) as a function of increasing water arsenic levels in male participants. A. RBC
and water arsenic. B. HCT/PCV and water arsenic. The red line indicates the mean and
black line indicates the median (n=103). *Statistically significant difference compared to
0 ≤ 10 µg/L (p≤0.05). # Statistically significant difference compared to 10 ≤ 100 µg/L
(p≤0.05). Data provided as courtesy of Dr. Faruque Parvez.
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Table 2.2. Hematology parameters in arsenic-exposed men.a,b
Hematology
Parameters

Water Arsenic (µg/L)
β (95% CI), p-value

Urinary As (µg/gm)
β (95% CI), p-value

RBC (x106/µL)

-0.13 (-0.19, -0.07), <0.0001*

-0.23 (-0.37, -0.09), 0.001*

HCT/PCV (%)

-0.68 (-1.17, -0.19), 0.008*

-1.08 (-2.2, 0.03), 0.06

MCV (fL)

0.67 (-0.16, 1.51), 0.11

1.43 (-0.41, 3.28), 0.13

Hgb (g/dL)

-0.06 (-0.18, 0.07), 0.33

-0.06 (-0.18, 0.07), 0.39

60.95 (-146.00, 267.9), 0.56

516.11 (70.16, 962.06), 0.02*

WBC (cell/cumm)
a

Red blood cells counts (RBC), hematocrit packed cell volume (HCT/PCV), mean
corpuscular volume (MCV), hemoglobin (Hgb), and total white blood cell counts (WBC).
b

Parameter estimates are adjusted for age, BMI, smoking status, PAH-DNA adduct, and
level of education *Significance level is p≤0.05.
Data provided as courtesy of Dr. Faruque Parvez.
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Relationships of urinary As metabolites and hematological parameters
We further examined the role of urinary As metabolites on hematological
parameters in adjusted models (Table 2.3). Associations between urinary As metabolites
and hematological parameters were consistent with those observed for water and urinary
As. As stated, we observed a significant inverse relationship between RBC and InAs (ß=
-0.16, 95% CI: -0.26, -0.23; p= 0.004), MMA (ß=-0.12, 95% CI: -0.21, -0.02; p= 0.01),
and DMA (ß= -0.11, 95% CI: -0.22, 0.11; p= 0.05). A significant inverse association of
InAs (ß= -0.12 95% CI: -0.21, -0.02; p= 0.01) with HCT/PCV was also found. We
observed a positive association of DMA with HCT/PCV (ß= 2.71, 95% CI: 0.62, 4.81;
p=0.01). There was a marginally significant inverse relationship between InAs and Hgb
(ß= -0.18, 95% CI: -0.39, 0.03; p=0.09) and this relationship was stronger among
smokers (ß= -0.27, 95% CI:-0.50, -0.04; p=0.02, data not shown). Significant negative
correlations were also found between percent lymphocytes and InAs (ß= -1.87, 95% CI:3.22.50, -0.53; p= 0.007), MMA (ß= -1.37, 95% CI:-2.57.50, -0.16; p= 0.02), and DMA
(ß= -1.45, 95% CI:-2.92, 0.02; p=0.05). Similarly, InAs was negatively correlated with
percent neutrophils (ß= 1.60, 95% CI: 0.09, 3.11; p=0.04).

48

Table 2.3. Hematology parameters and urinary arsenic metabolites of the study
participants.a,b
Hematology
Parameters
RBC
(x106/µL)
HCT/PCV
(%)
MCV (fL)
Hgb (g/dL)

In As (As+3 As+5)
(µg/L)

MMA (µg/L)

DMA (µg/L)

β (95% CI), p-value

β (95% CI), p-value

β (95% CI), p-value

-0.16 (-0.26, -0.05),
0.004*
-0.77 (-1.6, 0.06),
0.07

-0.12 (-0.21, -0.02),
0.01*
-0.54 (-1.27, 0.19),
0.15
0.58 (-0.63, 1.79),
0.34
-0.06 (-0.25, 0.12),
0.48
154.22 (-141.58,
450.02), 0.30
-1.37 (-2.57, -0.16),
0.02*

-0.11 (-0.23, 0.11),
0.05*
2.71 (0.62, 4.81),
0.01*
0.51 (-0.95, 1.97),
0.49
-0.05 (-0.27, 0.17),
0.65
181.07 (-177.05,
539.18), 0.32
-1.45 (-2.92, 0.02),
0.05*
1.29 (-0.32, 2.91),
0.11
-0.22 (-0.52, 0.07),
0.13
0.38 (-0.1, 0.86),
0.12

0.8 (-0.57, 2.18), 0.25
-0.18 (-0.39, 0.03),
0.09
224.14 (-113.31,
561.58), 0.19
-1.87 (-3.22, -0.53),
0.007*

WBC
(cells/cumm)
Lymphocytes
(%)
Neutrophils
1.6 (0.09, 3.11), 0.04*
(%)
Monocytes
-0.18 (-0.46, 0.09),
(%)
0.19
Eosinophils
0.43 (-0.02, 0.88),
(%)
0.06

1.13 (-0.2, 2.46), 0.09
-0.12 (-0.37, 0.12),
0.32
0.36 (-0.04, 0.75),
0.08

a

Red blood cells counts (RBC), hematocrit packed cell volume (HCT/PCV), mean
corpuscular volume (MCV), hemoglobin (Hgb), and total white blood cell counts (WBC).
b

Parameter estimates are adjusted for age, BMI, smoking status, PAH-DNA adduct, and
level of education.*Significance level is p≤0.05.
Data provided as courtesy of Dr. Faruque Parvez.
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Relationships of As exposure and hematological parameters by smoking status
Table 2.4 shows relationships between As exposure and hematological parameters
among smokers and non-smokers. Among non-smokers, the negative correlation with
RBC remained significant in relation to WAs. Interestingly, the magnitude of the
associations of As exposure, particularly with UAs on RBC (ß= -0.4, 95% CI: -0.66, 0.14; p= 0.005) as well as HCT/PCV (ß= -1.98, 95% CI: -4.19, 0.23; p= 0.08) became
stronger among smokers. Additionally, there was also a strong effect of UAs on Hgb
among smokers in relation to urinary As (β= -0.54, 95% CI: -1.09, 0.00; p= 0.05). In
contrast, a significant association was observed for WBC with WAs as well as UAs,
which was non-significant among smokers. We have found a marginally significant
interaction with water As and smoking (p=0.09) on RBC.
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Table 2.4. Hematology parameters in arsenic-exposed men by smoking status.a,b
Never Smokers

Hematology
Parameters
RBC
(x106/µL)
HCT/PCV
(%)
MCV (fL)
Hgb (g/dL)
WBC
(cells/cumm)

Water
Arsenic
(µg/L)
β (95% CI),
p-value
-0.09 (-0.15,
-0.03), 0.003*
-0.38 (-0.9,
0.14), 0.15
0.64 (-0.46,
1.73), 0.26
-0.02 (-0.17,
0.13), 0.8
239.36 (-2.07,
480.79), 0.05*

Smokers

Urinary
Arsenic
(µg/gm)
β (95% CI), pvalue
-0.1 (-0.24,
0.04), 0.17
-0.2 (-1.39,
0.99), 0.74
1.16 (-1.29,
3.61), 0.35
-0.02 (-0.34,
0.31), 0.92

Urinary
Arsenic
(µg/gm)
β (95% CI), pvalue
-0.17 (-0.3, -0.4 (-0.66, 0.04), 0.01*
0.14), 0.005*
-0.87 (-1.96,
-1.98 (-4.19,
0.21), 0.12
0.23), 0.08
0.87 (-0.65,
2.52 (-0.57,
2.4), 0.27
5.61), 0.11
-0.07 (-0.35,
-0.54 (-1.09,
0.21), 0.63
0.00), 0.05*
-279.95 (337.84 (776.17 (261.38,
677.24, 117.33),
495.65,
1290.96), 0.004*
0.17
1171.32), 0.43
Water Arsenic
(µg/L)
β (95% CI), pvalue

a

Red blood cells counts (RBC), hematocrit packed cell volume (HCT/PCV), mean
corpuscular volume (MCV), hemoglobin (Hgb), and total white blood cell counts (WBC).
b

Parameter estimates are adjusted for age, BMI, smoking status, PAH-DNA adduct, and
level of education. *Significance level is p<0.05.
Data provided as courtesy of Dr. Faruque Parvez.
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DISCUSSION

The goal of this study was to evaluate the effects of chronic drinking water As
exposure on clinical indicators of anemia among healthy male smokers and non-smokers
in the HEALS cohort living in rural Bangladesh. To our knowledge, the present study is
the first to investigate associations between As exposure (as indicated by WAs, UAs, and
UAs metabolites) and clinical indicators of anemia among smokers. A dose-dependent
reduction in RBC and HCT/PCV was found with increasing WAs levels. In models
adjusted for age, BMI, educational attainment, smoking, and PAH-DNA adducts, inverse
relationships were also found between measures of As exposure and RBC and HCT/PCV.
The correlations between As exposure with RBC and HCT/PCV became stronger among
smokers, suggesting potential interactive effects between As and smoking on clinical
indicators of anemia. Additionally, associations between As exposure and WBC and
white blood cell subsets were also identified.
A high prevalence of anemia exists among the general population in rural
Bangladesh (Ahmed 2000; Jamil et al., 2008). Anemia in this region is often associated
with nutritional deficiencies of iron, folate, and vitamins B6 and B12 (Ahmed 2000), but a
number of studies have also reported As exposure to be a contributing risk factor
(Hopenhayn et al., 2006; Heck et al., 2008; Surdu et al., 2015; Kile et al., 2016). Nearly
all of these referenced studies only included women, so there is a lack of information
concerning the relationships between As exposure and anemia among men. A previous
study by Heck et al. (2008), found that men exposed to elevated As were susceptible to
anemia, whereas only women with predispositions (i.e., Hgb <10 g/dL) showed a
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relationship between As exposure and anemia. These findings emphasize the need for
gaining a deeper understanding of the influences of As exposure and anemia among men.
As exposure has been reported to contribute to anemia in humans and rodents by
depressing the function of the bone marrow (Szymańska-Chabowska et al., 2002). A
number of studies have indicated As-induced toxicity to red blood cells (Winski et al.,
1997; Winski and Carter 1998; Zhang et al., 2000; Biswas et al., 2008; Mahmud et al.,
2009). As has been shown to cause oxidative stress, deplete intracellular ATP, and to
alter the morphological characteristics of red blood cells resulting in compromised
membrane integrity, eryptosis, and intra- and-extravascular hemolysis (Winski and Carter
1998; Biswas et al., 2008; Mahmud et al., 2009). There is also a possibility that the
inverse relationship between RBC and As exposure is related to reduced erythropoietic
capacity of the bone marrow. In fact, we recently reported that drinking water exposure
of adult male mice to low levels of As+3 (500 µg/L) disrupts erythropoiesis in the bone
marrow by inhibiting the colony-forming ability of early erythroid progenitors and
suppressing the differentiation of later stage erythroblasts (Medina et al., 2017).
The main form of As found in drinking water in Bangladesh is As+3 (Zheng et al.,
2004), which is the most toxic inorganic arsenical (Styblo et al., 2000). In the body, As+3
is metabolized through a series of oxidative methylation and reduction reactions
catalyzed by the As (+3 oxidation state) methyltransferase enzyme to monomethylarsonic
acid (MMA+5), monomethylarsonous acid (MMA+3), dimethylarsinic acid (DMA+5), and
dimethylarsinous acid (DMA+3) (Thomas et al., 2001; Vahter 2002). MMA+3 and DMA+3
are the most toxic forms of As and are considered more cytotoxic, genotoxic, and to exert
greater inhibitory effects on the activity of certain enzymes than As+3 (Thomas et al.,
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2001). MMA+5 and DMA+5 are the primary As metabolites excreted in urine and are less
acutely toxic than As+3 (Vahter and Concha 2001; Drobna et al., 2009).
The relative amounts of excreted MMA to DMA are used as indicators to
determine the efficiency of InAs metabolism and have been associated with severity of
toxicological outcomes in a number of studies (Mäki-Paakkanen et al., 1998; Gamble et
al., 2005; Steinmaus, et al., 2006; Kile et al., 2011; Li et al., 2013). Particularly, high
levels of DMA in urine are indicative of more efficient As metabolism and are often
associated with decreased toxicity (Vahter and Concha 2001; Vahter 2002). We found a
positive relationship between DMA and HCT/PCV, which likely reflects a greater As
metabolic capacity among some participants. Multiple As forms exist simultaneously in
the body (Vahter 2002), so it is possible that the discrepancy between the direction of
relationship with DMA and RBC was influenced by toxic effects caused by other As
metabolites.
Cigarette smoke has been shown to cause red blood cell hemolysis in animal
models and humans (Minamisawa et al., 1990; Masilamani et al., 2016). In a group of 62
men and women, Masilamani et al., (2016) recently found that smoking causes
morphological abnormalities on the surface of red blood cells that result in hemolysis.
The authors also indicate that such cell surface damage facilitates the entry of toxins into
red blood cells (Masilamani et al., 2016). The stronger relationships identified between
RBC and HCT/PCV in smokers may therefore be attributed to potential interactive
effects on red blood cell hemolysis induced by combined exposure to As and cigarette
smoke. However, this hypothesis requires further investigation. The inverse relationship
between UAs and Hgb is consistent with previous findings that As binds to heme and
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reduces heme metabolism resulting in decreased Hgb levels in red blood cells
(Delnomdedieu et al., 1994; Hernández-Zavala et al., 1999; Lu et al., 2004). It is
interesting to note that this association was detected only among smokers. Previous
studies have indicated elevated RBC and HCT/PCV among smokers (Sagone and
Balcerzak 1975; Nordenberg et al., 1990; Anandha, et al., 2014), but these studies did not
consider the effects of combined exposures with other pollutants. This suggests that
smoking may have differential effects on red blood cells when combined with other
toxicants, such as As.
Interestingly, As exposure and smoking were correlated with hematological
indicators of immune status (i.e., WBC and white blood cell subsets). The loss of positive
associations between As exposure and WBC among smokers as well as the inverse
relationships between all UAs metabolites and lymphocyte percentages suggest potential
immune alterations among study participants and will be the topic of our future
investigations.
In summary, results from this study provide evidence that chronic drinking water
exposure to As results in hematological alterations that are consistent with anemia in a
male cohort of smokers and non-smokers in rural Bangladesh. In addition, we also found
that smoking may exacerbate As-induced effects on clinical indicators of anemia.
Collectively, these findings show that men are sensitive to As-induced anemia and
emphasize the necessity for further research concerning the mechanistic basis for the
relationship between chronic As exposure and anemia.
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KEY POINTS

•

Exposure to 500 ppb As+3 reduced MCH levels in adult male mice.

•

BFU-E colony formation was attenuated by exposure to 500 ppb As+3.

•

Male mice exposed to 500 ppb As+3 had elevated serum levels of EPO.

•

Erythropoiesis was impaired in 500 ppb As+3 exposed male mice.
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ABSTRACT

Epidemiological studies report an association between chronic arsenic (As)
exposure and anemia in men, and women who are predisposed to anemia. The purpose of
these studies was to determine whether a 60-d drinking water exposure of adult male
C57BL/6J mice to 0, 100, and 500 ppb arsenite (As+3) results in anemia due to alterations
in erythroid progenitor cell development in the bone marrow. Exposure to 500 ppb As+3
for 60 d resulted in a reduction of mean corpuscular hemoglobin (MCH) levels but did
not significantly alter reticulocyte (Retic.) counts, red blood cell (RBC) counts,
hemoglobin (Hgb) levels, mean corpuscular Hgb concentrations (MCHC), or mean
corpuscular volumes (MCV). Attenuation of burst-forming unit-erythroid (BFU-E)
colony formation was observed in bone marrow cells of mice exposed to 500 ppb As+3.
The differentiation of late stage bone marrow erythroblasts was reduced with the 500 ppb
As+3 exposure. Mice exposed to 500 ppb As+3 also had elevated serum levels of
erythropoietin (EPO). Collectively, these results show that exposure to environmentally
relevant levels of As+3 attenuates the development of early BFU-E cells and reduces the
differentiation of later stage erythroblasts. This suppression of bone marrow
erythropoiesis may be a contributing factor to the mild hypochromic anemia observed in
500 ppb As+3 exposed mice.
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INTRODUCTION

As is a widespread environmental toxicant and common contaminant in food and
drinking water (WHO 2011; Naujokas et al., 2013). Many people are chronically exposed
to levels of As in their drinking water that exceed the World Health Organization and
United States Environmental Protection Agency maximum contaminant level of 10 ppb
(U.S. EPA 2012; WHO 2011). As occurs in the environment in organic and inorganic
forms with multiple valence states (i.e., +3 or +5) that have differential toxicological
profiles (Petrick et al., 2001; Styblo et al., 2000; Szymańska-Chabowska et al., 2002).
As+3 is commonly found in drinking water and is the most toxic inorganic form of As
(Styblo et al., 2000; Naujokas et al., 2013). Exposure to elevated levels of As+3 has been
documented to exert a multitude of detrimental health outcomes, including cancers,
cardiovascular diseases, immunosuppression, and anemia (Hughes 2002; Heck et al.,
2008; Naujokas et al., 2013; Ferrario et al., 2016).
Anemia is classified as a decrease in the number of RBCs and/or reduced Hgb
levels in circulating RBCs (WHO 2015). Multiple epidemiological studies report an
association between chronic As exposure and anemia (Heck et al., 2008; Surdu et al.,
2015; Kile et al., 2016). Heck et al. (2008), found that low Hgb levels (<10 g/dL) were
negatively associated with urinary As concentrations (>200 ppb) in men and women
living in Bangladesh. Pregnant women exposed to elevated levels of As in their drinking
water are particularly susceptible to developing anemia (Hopenhayn et al., 2006; Surdu et
al., 2015). Findings from these studies emphasize the need to develop a clear
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understanding of the relationship between environmentally relevant As+3 exposures and
anemia.
The bone marrow is very sensitive to As-induced toxicity (SzymańskaChabowska et al., 2002; Ezeh et al., 2014; Ezeh et al., 2016a; Xu et al., 2016b) and is the
major site of erythropoiesis in adult humans and mice (Tsiftsoglou et al., 2009; Dzierzak
and Philipsen, 2013). Erythropoiesis is regulated by EPO released from the kidney in
response to hypoxic conditions in the body (Hattangadi et al., 2011). Increased EPO
levels stimulate the proliferation and differentiation of early erythroid progenitor cells in
the bone marrow (Hattangadi et al., 2011). The first stage of erythroblast differentiation is
BFU-E, which respond to increased EPO and other growth factors (e.g., SCF, IL-3, IL-6)
to proliferate and mature to the highly EPO responsive colony-forming unit-erythroid
(CFU-E) stage (Hattangadi et al., 2011). At the CFU-E stage, Hgb production is initiated,
and the cells undergo four additional stages of differentiation (i.e., proerythroblast,
basophilc, polychromatophilic, and orthochromatophilic), prior to enucleation and release
from bone marrow into the circulation (Migliaccio, 2010; Elliott and Sinclair, 2012).
The purpose of this study was to determine whether a 60-d drinking water
exposure of adult male C57BL/6J mice to environmentally relevant levels of As+3 (0,
100, and 500 ppb) results in anemia. As a potential target for As+3-induced toxicity with
relevance to anemia, we evaluated the colony forming ability and differentiation of early
erythroid progenitor cells in the bone marrow.
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MATERIAL AND METHODS

Chemicals and reagents
Sodium meta-arsenite (CAS 774-46-5, Cat. No. S7400), Dulbecco’s phosphate
buffered saline w/o Ca+2 or Mg+2 (DPBS-), thiazole orange (Cat. No. 390062), and
Isocove’s Modified Dulbecco’s Medium were purchased from Sigma-Aldrich (St. Louis,
MO). Hanks Balanced Salt Solution (HBSS) was purchased from Lonza (Walkersville,
MD). Fetal Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery
Branch, GA). Penicillin/Streptomycin 10,000 (mg/ml)/10,000 (U/ml) and 200 mM LGlutamine was purchased from Life Technologies (Grand Island, NY). Serum-free
methylcellulose-based medium containing EPO for culture of mouse erythroid cells (Cat.
No. SF M3436) was purchased from STEMCELL Technologies (Cambridge, MA).
FITC rat anti-mouse Ter119 clone Ter119 (Cat. No. 557915) and PE rat anti-mouse
CD71 clone C2 (Cat. No. 553267) antibodies were purchased from BD Biosciences (San
Jose, CA). Cellometer acridine orange/propidium iodide (AO/PI) staining solution in PBS
(Cat. No. CS2-0106-5ML) was purchased from Nexcelom Bioscience (Manchester, UK).
Mouse EPO Quantikine® ELISA kit (Cat. No. MEP00B) was purchased from R&D
Systems (Minneapolis, MN).
Mouse drinking water exposures
All experiments were performed in accordance with protocols approved by the
Institutional Animal Use and Care Committee at the University of New Mexico Health
Sciences Center. Male C57BL/6J mice were purchased at 8 weeks of age from Jackson
Laboratory (Bar Harbor, ME) and allowed to acclimate in our animal facility for one
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week prior to the onset of experiments. Mice were maintained on a 12:12 reverse
light:dark cycle and were fed 2020X Teklad global soy protein-free rodent diet (Envigo,
Indianapolis, IN) throughout the experiment.
Mice were housed 2-3 individuals per cage and exposed to 0 (control), 100, or
500 ppb As+3 in their drinking water for 60 d (n = 5 mice/group). As+3 doses were
prepared fresh weekly by weighing each water bag and determining the appropriate
volume of stock As+3 to add into each bag to yield 100 or 500 ppb As+3. Water bags were
collected and weighed at the end of each week and the change in weight was used to
estimate water consumption by mice in each cage.
Primary bone marrow cell isolation
Bone marrow cells were isolated as previously described (Ezeh et al., 2016b).
Both femurs from each mouse were harvested and placed into cold HBSS. Femurs were
then transferred into a 60 mm dish with HBSS to trim excess tissue from the bone.
Trimmed femurs were placed into a 60 mm dish containing 5 mL cold colony-forming
unit (CFU) medium (Isocove’s Modified Dulbecco’s Medium supplemented with 2%
heat inactivated FBS, 2 mM L-glutamine, and 100 mg/ml streptomycin and 100 units/ml
penicillin) and the ends of each femur were carefully cut to reveal the interior marrow
shaft. Bone marrow cells were flushed from each femur by passing approximately 6-9
mL of CFU medium through the marrow shaft using a 1cc syringe and 25-G needle. The
cell suspensions were then transferred to a 15 mL centrifuge tube, centrifuged at 200 xg
for 10 mins, and resuspended in 5 mL of CFU medium. Cell viabilities and
concentrations were determined using AO/PI staining and a Nexcelom Cellometer® Auto
2000 (Nexcelom Bioscience, Manchester, UK).
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Blood collection, serum preparation, and hematological analysis
Whole blood and blood for serum preparation was collected at the time of
sacrifice by cardiac puncture into EDTA coated 250µL tubes or 1.5 mL microcentrifuge
tubes, respectively. Hematological analysis of whole blood was performed using an
Abaxis VetScan HM5 hematology analyzer (Abaxis, Union City, CA). For serum
preparation, blood was clotted for 2 h at room temperature (RT). Clotted blood was
centrifuged at 2000 xg for 30 mins and serum was carefully removed and transferred to a
clean 1.5 mL microcentrifuge tube for storage at -80˚C.
BFU-E assay
Mouse BFU-E assays were setup following manufacturer’s instructions described
in version 3.4.0 of STEMCELL Technologies Technical Manual for Mouse ColonyForming Unit Assays using MethoCult™. Bone marrow cells from both femurs of each
mouse were pooled and resuspended to 1×106 cells/mL in CFU medium. 400 µL of the
1×106 cells/mL solution (4×105 cells) was transferred into 4 mL SF M3436
methylcellulose-based medium containing EPO to promote BFU-E development and
expansion. Samples were then mixed thoroughly by vortexing and held for approximately
10 mins to allow bubbles to dissipate. 1 mL (1×105 cells) of each sample solution was
then transferred in triplicate to treated 35 mm culture dishes (STEMCELL Technologies,
Cambridge, MA) using a 5cc syringe and a 16-G blunt-end needle. Each plate was then
gently rocked back and forth to evenly distribute the media across the surface of the dish.
Two culture dishes and one uncovered 35 mm dish containing 3 mL of sterile water were
placed into a covered 100 mm dish and incubated at 37˚C in humidified incubator with
5% CO2 for 14 d. After 14 d of culture, BFU-E colonies containing at least 30 cells were
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counted based on morphology using a dissecting microscope. Colony counts are reported
as the number of BFU-E colonies per million bone marrow cells.
Flow cytometry
Whole blood (non-coagulated) from each mouse was stained with 0.01 mg/mL
thiazole orange at RT for 30 mins (as described by BD Biosciences ReticCount
procedure, available: http://www.bdbiosciences.com/ds/is/tds/23-1789.pdf) and
reticulocytes were measured by flow cytometry using an Accuri™ C6 flow cytometer.
Total reticulocyte counts (ARC) were obtained using the following formula: TRC = (%
reticulocytes/100) x RBC counts/L.
Bone marrow erythroblast subsets were evaluated based on CD71 and Ter119
surface marker expression. 1×106 bone marrow cells from each mouse were transferred to
12x75 mm tubes and stained in 100 µL of flow stain/wash buffer (DPBS- with 2% heat
inactivated FBS and 0.09% sodium azide) with 0.5 µg of rat anti-mouse CD71-PE and rat
anti-mouse Ter119-FITC monoclonal antibodies at RT for 30 mins. Samples were then
washed twice with flow stain/wash buffer. After the final wash, samples were
resuspended in 0.5 mL flow stain/wash buffer and analyzed using an Accuri™ C6 flow
cytometer (BD Biosciences, San Jose, CA).
Mouse EPO ELISA
Serum EPO levels were measured using the Mouse EPO Quantikine® ELISA kit
according to manufacturer’s instructions. Briefly, serum samples and EPO standards were
diluted two-fold and 50 µL of each sample was added in duplicate to the appropriate
wells of a microplate pre-coated with an EPO specific monoclonal antibody. The plate
was then covered and incubated at RT for 2 h on a microplate shaker. Following
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incubation, the plate was washed five times. After the last wash, the plate was emptied
and 100 µL of mouse EPO monoclonal antibody conjugated to horse radish peroxidase
was added to each well and incubated at RT for 2 h on a microplate shaker. The plate was
washed again and 100 µL of substrate solution (hydrogen peroxide and
tetramethylbenzidine) was added to each well and incubated at RT for 30 mins.
Colorimetric reactions were stopped by adding 100 µL of 0.25 N hydrochloric acid to
each well and the absorbance was read immediately at 450 nm and 540 nm using a
SpectraMax® 340PC microplate reader (Molecular Devices, Sunnyvale, CA). Readings
at 540 nm were subtracted from those at 450 nm to correct for optical imperfections in
the plate and the corrected values were used for subsequent analysis. Sample
concentrations were determined using a four-parameter logistic standard curve.
Statistics
Data was analyzed using Sigma Plot 12.5 software. Five mice (n = 5) were
assigned to each exposure group and unless otherwise specified in figure legends were
utilized in statistical analysis. Differences between control and As+3 exposure groups
were determined using a Student’s t-test at a significance level of p<0.05.

66

RESULTS

Hematological effects of drinking water exposure in adult mice
Adult male C57BL/6J mice were exposed to 0, 100, and 500 ppb As+3 via their
drinking water for 60 d. There were no differences in body weights in any of the As+3
exposure groups. A slight decrease in water consumption in the 100 ppb As+3 exposure
group was observed, but this effect was not dose-dependent (Table 3.1). To determine
whether As+3 exposure results in the development of anemia, RBC counts, Hgb levels,
MCHCs, MCH levels, and MCVs were measured in whole blood using an Abaxis
VetScan hematology analyzer. Mice exposed to 500 ppb As+3 had significantly lower
MCH levels than control mice (Table 3.2). Although not statistically significant, a trend
of decrease in MCHCs and Hgb levels was also noted in mice exposed to 500 ppb As+3
(Table 3.2). There were no changes in total retic counts, RBC counts, or MCVs with
either of the As+3 doses (Table 3.2). These results imply that exposure to 500 ppb As+3
for 60 d resulted in a moderate Hgb reduction consistent with hypochromic anemia.
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Table 3.1. Body weights and drinking water consumption of male C57BL/6J mice
exposed via drinking water to 0, 100, and 500 ppb As+3 for 60 d.a
Treatment

Body Weight (g)

Water Intake (mL/day)

Control

34.42 ± 2.36

3.66 ± 0.29

100 ppb

32.76 ± 3.41

3.10 ± 0.13*

500 ppb

33.30 ± 1.36

3.77 ± 0.57

a

Mice were 9-week old at the start of the As+3 exposure. Water consumption was
monitored weekly based on weight change of the water bags. Data are expressed as mean
± SD (n = 5 mice/group).
*Statistically significant difference compared to control (p<0.05).
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Table 3.2. Retic. counts, RBC counts, Hgb levels, MCH levels, MCHCs, and MCVs in
whole blood collected from mice exposed via drinking water to 0, 100, and 500 ppb As+3
for 60 d.a
Parameter

Control

Retic. (x109 cells/L) 352.09 ± 16.96

100 ppb As+3

500 ppb As+3

359.01 ± 23.63

379.38 ± 35.86

RBC (x1012/L)

10.85 ± 0.35

11.11 ± 0.27

10.99 ± 0.23

Hgb (g/dL)

17.16 ± 0.52

17.26 ± 0.18

16.76 ± 0.38

MCH (pg)

15.80 ± 0.16

15.56 ± 0.27

15.24 ± 0.46*

MCHC (g/dL)

35.92 ± 0.36

35.26 ± 0.63

34.94 ± 1.20

MCV (fL)

43.80 ± 0.45

44.20 ± 0.45

43.80 ± 0.45

a

Hematology analysis was performed using an Abaxis VetScan hematology analyzer.
Data are expressed as mean ± SD (n = 5 mice/group).
*Statistically significant difference compared to control (p<0.05).
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Bone marrow BFU-E colony formation was attenuated by As+3 exposure
To determine whether alterations in erythroid progenitor cell development is a
target of As+3 toxicity, we evaluated the colony-forming ability of BFU-E cells from the
bone marrow of mice exposed to 0, 100, and 500 ppb As+3 for 60 d. Bone marrow cells
were cultured ex vivo in serum free methylcellulose-based medium containing EPO for
14 days and the number of BFU-E colonies was determined based on morphology using a
dissecting microscope. A significant reduction in the number of BFU-E colonies was
observed in mice exposed to 500 ppb As+3 (Figure 3.1A). Another interesting observation
was BFU-E colonies from the bone marrow of 500 ppb As+3 exposed mice were not as
dense as control colonies, which is indicative of suppressed proliferation, delayed
differentiation, and/or reduced cell viability (Figure 3.1B). There were no statistically
significant changes in BFU-E colony formation with the 100 ppb As+3 exposure (Figure
3.1A).
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Figure 3.1. BFU-E colony formation in bone marrow of male C57BL/6J mice exposed to
0, 100, and 500 ppb As+3 for 60 d. A. Number of BFU-E colonies per million bone
marrow cells cultured ex vivo in serum free methylcellulose-based medium containing
EPO for 14 days. B. Representative BFU-E colony images from 0, 100, and 500 ppb As+3
exposed mice. Data are expressed as mean ± SD of triplicate cultures per mouse (n = 4-5
mice/group). *Statistically significant difference compared to control (p<0.05).
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Suppressed differentiation of late-stage erythroid progenitors in the bone marrow of
mice exposed to As+3
Based on the finding that As+3 attenuates BFU-E development, we investigated
whether the downstream bone marrow erythroblast population subsets were also altered.
Stages of erythroblast differentiation can be defined based on CD71 and Ter119 surface
marker expression using flow cytometry (Socolovsky et al., 2001; Lau et al., 2012).
Erythroblast subsets in bone marrow were defined as follows: (I) proerythroblast:
CD71high/Ter119med, (II) basophilic erythroblast: CD71high/Ter119high, (III) = late
basophilic and polychromatophilic erythroblasts CD71med/Ter119high, and (IV) =
orthochromatophilic erythroblasts CD71low/-/Ter119high (Figure 3.2A). As+3 exposure at
500 ppb caused a significant decrease in the percentage of late stage orthochromatophic
erythroblasts (Figure 3.2B). No differences in other erythroblast subsets (I-III) were
detected for either of the As+3 exposures (Figure 3.2B). These results indicate that As+3
also alters the differentiation of late stage erythroid progenitors in the bone marrow.
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Figure 3.2. Erythroblast subsets in bone marrow of male C57BL/6J mice exposed to 0,
100, and 500 ppb As+3 in drinking water for 60 d. Bone marrow cells were stained with
CD71 and Ter119 surface markers and analyzed on a flow cytometer. A. Flow cytometry
gating strategy used to define erythroblast subsets (I-IV) in mouse bone marrow cells. B.
% erythroblast subsets defined based on CD71 and Ter119 surface marker expression.
Data are expressed as mean ± SD (n = 5 mice/group). *Statistically significant difference
compared to control (p<0.05).
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Serum EPO levels were elevated in As+3 exposed mice
To evaluate whether disrupted erythropoiesis in the bone marrow (i.e., attenuated
BFU-E colony-formation and suppressed differentiation of later stage erythroblasts) was
accompanied by an increase in circulating EPO levels in As+3 exposed mice, the
concentration of EPO in serum was analyzed using a mouse EPO ELISA kit. A
significant increase in EPO concentrations was detected in serum from 500 ppb As+3
exposed mice (Figure 3.3). There was no difference in serum EPO levels in 100 ppb As+3
exposed mice (Figure 3.3). These findings suggest that suppressed erythropoiesis in the
bone marrow of 500 ppb As+3 exposed mice stimulated EPO release from the kidneys.
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Figure 3.3. EPO concentrations (pg/mL) in serum from male C57BL/6J mice exposed to
0, 100, and 500 ppb As+3 via drinking water for 60 d. Serum EPO concentrations were
determined using a mouse EPO ELISA. Red line indicates the mean and black line
indicates the median (n = 4-5 mice/group). *Statistically significant difference compared
to control (p<0.05).
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DISCUSSION

In the present study, we evaluated whether a 60-d drinking water exposure of
adult male C57BL/6J mice to environmentally relevant levels of As+3 (0, 100, and 500
ppb) would result in anemia. Mice exposed to 500 ppb As+3 had significantly lower MCH
levels and also showed a non-statistically significant trend of decrease in MCHCs and
Hgb levels (Table 3.2). RBC counts and MCVs were not altered with either of the As+3
exposures (Table 3.2). This is consistent with previous findings that As reduces heme
metabolism and can bind to Hgb, which results in decreased Hgb concentrations in RBCs
(Delnomdedieu et al., 1994; Hernández-Zavala et al., 1999; Lu et al., 2004). Acute high
level As+3 exposure in humans and rodents has been reported to result in anemia as a
result of bone marrow depression (Szymańska-Chabowska et al., 2002). Morse et al.
(1980), showed an inhibition of iron incorporation in circulating RBCs along with
suppressed proliferation of early erythrocytes from the bone marrow of mice injected
with high levels of As+3. These studies provide evidence that acute high level As
exposures can cause anemia in mice.
The bone marrow is the major site of erythropoiesis in humans and mice
(Tsiftsoglo et al., 2009; Dzierzak and Philipsen, 2013). Several studies have shown that
hematopoietic progenitor cells in the bone marrow are sensitive to low levels of As+3 in
vivo and in vitro (Ferrario et al., 2008; Ezeh et al., 2014; Ezeh et al., 2016a). As a
potential target for As+3-induced toxicity, we evaluated the development of BFU-E cells
in the bone marrow. BFU-E cells are the earliest stage of erythroid cell development and
they can be readily assessed based on colony formation in methylcellulose-based
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medium. BFU-E colony formation was only attenuated in bone marrow cells from 500
ppb As+3 exposed mice (Figure 3.1). BFU-E colonies from 500 ppb As+3 exposed mice
were also less dense than control colonies, indicating compromised development of the
cells likely as result of decreases in cell viability, proliferation, and/or differentiation
capacity (Figure 3.1B).
To assess whether As+3 altered downstream erythroblast differentiation, we
evaluated erythroblast subsets in bone marrow based on CD71 and Ter119 surface
marker expression. The stages of erythroblast differentiation were identified based on the
degree of CD71 and Ter119 surface marker expression using flow cytometry (Figure
3.2A). Interestingly, only the latest stage of erythroblast differentiation (i.e., stage IV,
orthrochromatophilic erythroblasts) was reduced in 500 ppb As+3 mice (Figure 3.2B).
This provides evidence that As+3 not only attenuates the development of early BFU-E
cells, but it also reduces the differentiation of later stage erythroblasts. Taken together,
these results show that different stages of erythroid cell development may have
differential sensitives to As+3.
Our group previously reported that mice exposed to 500 ppb As+3 in their
drinking water for 30 d had elevated As levels in the bone marrow (Xu et al., 2016b). It
has also been shown that As+3 and MMA+3 can inhibit the development of pre-B cells in
the bone marrow by reducing STAT5 activation (Ezeh et al., 2016a). Since the
maturation of erythroid progenitor cells is also dependent on STAT5 signaling
(Socolovsky et al., 1999; 2001), it is likely that the attenuation of BFU-E colony
formation may be, at least in part, attributed to interference with this signaling pathway.
As+3 has also been shown to inhibit the function of C3 and C4 zinc finger proteins by
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replacing zinc on the zinc fingers (Zhou et al., 2011; Zhou et al., 2014). Many of the
transcription factors that regulate the expression of genes critical for development of
early erythroid progenitors are zinc fingers with motifs that can be displaced by As+3
(Hattangadi et al., 2011). It is therefore possible that As+3 may be suppressing the
development of early erythroid progenitors by inhibiting the function of these essential
zinc finger transcription factors.
Mice exposed to 500 ppb As+3 also exhibited increased levels of EPO in their
serum (Figure 3.3). Increased circulating EPO levels is likely a physiological attempt to
cope with the loss of erythropoietic function in the bone marrow. In mice the spleen plays
a critical role in maintaining erythropoiesis during conditions of hypoxic stress, such as
experienced when the bone marrow is not capable of producing adequate amounts of
RBCs to meet physiological demands (Socolovsky 2007; Paulson et al., 2011; Dzierzak
and Philipsen, 2013). Compensation from the spleen for the loss of erythropoietic
capacity in the bone marrow is likely responsible for the stable RBC counts observed
with the 60 d As+3 exposure. In support, As+3 exposed mice not only exhibited elevated
circulating EPO levels, but also showed slight trends of increase in total retic and RBC
counts. However, further studies are needed to determine whether As+3-induced
disruption of bone marrow erythropoiesis causes activation of stress erythropoiesis in the
spleen. Taking findings from epidemiological studies into consideration, it is also
possible that a longer exposure duration, such as that experienced by chronically exposed
human populations, may result in reduced RBC counts and further diminished Hgb
levels.
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Results from this study show that 60 d drinking water exposure to
environmentally relevant levels of As+3 in adult male mice results in a moderate Hgb
reduction that is consistent with hypochromic anemia. In addition, it was found that 500
ppb As+3 disrupts erythropoiesis in the bone marrow by attenuating the colony-forming
ability of early BFU-E cells and reducing the differentiation of later stage erythroblasts.
Collectively, these findings provide initial insights into a possible means by which As+3
exposures can contribute to the development of anemia in chronically exposed
individuals.
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KEY POINTS

•

Arsenic, a widespread environmental toxicant, impairs bone marrow erythropoiesis
by selective disruption of GATA-1 function.

•

Dysregulation of erythropoiesis is a likely mechanism underlying the high prevalence
of anemia in people chronically exposed to arsenic.
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ABSTRACT

Anemia is a hematological disorder that adversely affects the health of millions of
people worldwide. Although many variables influence the development and exacerbation
of anemia, one major contributing factor is the impairment of erythropoiesis. Normal
erythropoiesis is regulated by the zinc finger (ZF) transcription factor GATA-1.
Disruption of the ZF motifs in GATA-1, such as produced by germline mutations,
compromises the function of this critical transcription factor and cause dyserythropoietic
anemia. Utilizing a combination of in vitro and in vivo studies, we demonstrate that
arsenic, a widespread environmental toxicant, selectively inhibits erythropoiesis through
the disruption of GATA-1 ZF motifs. We found that arsenic selectively interacts with ZF
motifs of GATA-1, causing zinc loss, and inhibition of DNA and protein binding
activities, resulting in dyserythropoiesis and an imbalance of hematopoietic
differentiation. For the first time, we show that exposures to a prevalent environmental
contaminant compromise the function of a key regulator of erythropoiesis, producing
effects functionally similar to inherited GATA-1 mutations. These findings provide
insights into a novel mechanism by which arsenic exposure can cause anemia and
provide critical insights into potential prevention and intervention for arsenic-related
anemias.
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INTRODUCTION

Anemia is a hematological disorder that affects approximately 25% of the
population globally (WHO 2015). A major cause of anemia is decreased red blood cell
(RBC) production (Hodges et al., 2007; Gangat and Wolanskyj 2013; Koury 2014),
which occurs primarily in the bone marrow (BM). RBCs are produced through
erythropoiesis starting from hematopoietic stem cells (HSC) (Fujiwara et al., 2009;
Dzierzak and Philipsen 2013). HSCs differentiate to common myeloid progenitors
(CMP), which depending on expression levels and subsequent functional antagonism of
two key transcriptional regulators, GATA-1 and PU.1, commit to either erythromegakaryocytic or myeloid lineages, respectively (Zhang et al., 1996; Nerlov et al., 2000;
Hsu et al., 2001; Rhodes et al., 2005; Iwasaki and Akashi 2007). Once committed to the
erythro-megakaryocytic lineage, megakaryocyte-erythroid progenitors (MEPs)
differentiate to megakaryocyte and erythroid progenitors (Dzierzak and Philipsen 2013).
The earliest committed erythroid progenitors are detected as slowly proliferating burstforming unit erythroid cells (BFU-E). BFU-Es differentiate into rapidly dividing colonyforming unit erythroid cells (CFU-E) (Dzierzak and Philipsen 2013). CFU-Es further
differentiate through multiple stages and undergo many substantial changes to finally
produce mature RBCs (Dzierzak and Philipsen 2013).
Erythropoiesis is a dynamic and precisely regulated process under the control of
many regulatory factors (Pevny et al., 1991; Fujiwara et al., 1996; Hattangadi et al.,
2011), among which GATA-1 is recognized as the master regulator of erythropoiesis and
its activity is necessary for the normal differentiation of erythroid progenitors (Weiss and
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Orkin 1995; Fujiwara et al., 1996; Ferreira et al., 2005). GATA-1 is the founding member
of the GATA family of transcription factors and is a crucial regulator of genes encoding
hemoglobin subunits and heme biosynthetic enzymes (Evans et al., 1988; Pevny et al.,
1991; Pevny et al., 1995; Welch et al., 2004). GATA-1-dependent mechanisms constitute
an essential regulatory core that achieves physiological control of hemoglobin synthesis
(Katsumura et al., 2013). The function of GATA-1 depends on two zinc finger (ZF)
domains (Liew et al., 2005). The N- and C-terminal ZFs are responsible for binding to an
important co-factor, friend of GATA-1 (FOG-1) and DNA, respectively (Fox et al., 1999;
Liew et al., 2005; Bates et al., 2008). Mutation, protein level alteration, or dysfunction of
GATA-1 results in the inhibition of erythropoiesis (Pevny et al., 1991; Pevny et al., 1995;
Del Vecchio et al., 2005; Ciovacco et al., 2008; Crispino and Horwitz 2017). Zinc finger
dysfunction caused by mutations in the ZF motifs of GATA-1 is a characteristic
phenotype of inherited dyserythropoietic anemia (Ciovacco et al., 2008; Del Vecchio et
al., 2005; Crispino and Horwitz 2017).
Arsenic (As) is a widespread environmental toxicant that poses a significant threat
to public health. Millions of people worldwide are chronically exposed to inorganic
trivalent As (arsenite, AsIII) in drinking water at levels exceeding the World Health
Organization and United States Environmental Protection Agency maximum contaminant
level of 10 µg/L (WHO 2011; U.S. EPA 2012). Arsenic levels up to 1700 μg/L have been
measured in surface water in the United States (ATSDR 2016) and 12% of water supplies
in the north central and western regions have levels >20 μg/L (0.26 μM), with much
higher levels occurring in unregulated well water (ATSDR 2007, 2016). Exposure to As
is well documented to produce many acute and chronic health effects including, anemia
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(Hopenhayn et al., 2006; Heck et al., 2008; US EPA 2012; Vigeh et al., 2015; Surdu et
al., 2015; ATSDR 2016; Kile et al., 2016; Parvez et al., 2017). We reported that AsIII
exposure correlates with a decrease in RBC counts in a cohort of men from rural
Bangladesh exposed to a wide range of AsIII concentrations in their drinking water
(Parvez et al., 2017). Our previous work also showed that low-level AsIII exposure
causes anemia through inhibition of erythropoiesis in mice (Medina et al., 2017), but the
molecular mechanism of As-caused anemia is still unknown.
Our work on AsIII carcinogenesis demonstrated that ZF DNA repair proteins,
such as poly (ADP-ribose) polymerase 1 (PARP-1), are highly sensitive molecular targets
of AsIII (Ding et al., 2009; Zhou et al., 2011; Sun et al., 2014; Zhou et al., 2015). AsIII
interacts with the ZF domain, causing zinc loss, and dysfunction of the PARP-1 protein
(Ding et al., 2009; Sun et al., 2014). AsIII selectively interacts with ZFs containing ≥3
cysteine residues (Zhou et al., 2011), making ZF proteins containing at least 3 cysteines,
which are a minority in the ZF protein family, extremely sensitive to AsIII exposure.
Inspired by our previous work, we hypothesized that As-induced inhibition of
erythropoiesis may be attributed to loss of GATA-1 function, resulting from selective
interaction of AsIII with the ZFs on GATA-1, which are C4 (4 cysteines) configuration.
Here, we report that GATA-1 is a sensitive molecular target of AsIII exposure at
environmentally relevant concentrations. Our findings demonstrate, for the first time, that
exposure to a widespread environmental metal disrupts the function of GATA-1, the key
regulator of RBC development, resulting in the inhibition of erythropoiesis. The results
presented here highlight a novel mechanism by which AsIII exposure causes anemia, and
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also illustrate that arsenic influences the lineage commitment of hematopoietic progenitor
cells (HPC) by differential interactions with key regulatory proteins.
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MATERIALS AND METHODS

Chemicals
Sodium meta-arsenite (>95% purity), hemin, phorbol 12-myristate 13-acetate
(PMA), and benzidine stain were purchased from Sigma-Aldrich.
Cell culture and chemical-induced differentiation of K562 cells
Human leukemic cell line K562 was purchased from ATCC. K562 cells were
maintained in DMEM with 10% FBS according to instructions from ATCC. Erythroid
and megakaryocytic, myelocytic, and monocytic differentiation of K562 cells was
induced by 24 h treatment with 5 μM hemin or 5 ng/mL PMA as described previously,
respectively (Villeval et al., 1983; Shelly et al., 1998; Palma et al., 2012; Huang et al.,
2014). Differentiation status of K562 cells was determined based as follows:
erythropoietic (CD71, and benzidine staining) (Hafner et al., 1995), megakaryocytic
(CD41), myelocytic (CD11b), and monocytic (CD11b and forward scatter). Surface
marker antibodies were purchased from ThermoFisher Scientific. See below for a
detailed description of flow cytometry staining procedure.
Mice and in vivo drinking water exposures
Experiments involving mice were performed in accordance with protocols
approved by the Institutional Animal Use and Care Committee at the University of New
Mexico Health Sciences Center. Male C57BL/6J mice were purchased from Jackson
Laboratory and acclimated in our facility for one week prior to in vivo and in vitro
experiments. Mice were maintained on a 12:12 reverse light:dark cycle and fed 2920X
Teklad global soy protein-free rodent diet (Envigo, Indianapolis, IN) ad libitum. Mice

89

were exposed via their drinking water to 0 µg/L (control), 20 µg/L, 100 µg/L, and 500
µg/L or to 0 µg/L (control), 500 µg/L, and 1 mg/L As+3 for 30 days (n = 5 mice/group) or
2 weeks (n = 6 mice/group), respectively. Stock As+3 solutions were prepared at the onset
of each experiment at a concentration 1000 times greater (1000X) than the desired dose.
The volume of stock 1000X As+3 added to drinking water pouches to yield the desired
exposure doses was determined by weighing each pouch and subtracting the total weight
of the pouch and injection port to estimate the total water volume (1 g water ≈ 1 mL).
Primary mouse bone marrow cell isolation
BM cells were isolated from femur bones as described in detail by Ezeh et al.,
(2016b). Femurs from each mouse were flushed using a 1 mL syringe and 25-G needle.
The cell suspension was transferred to a 15 mL centrifuge tube, centrifuged at 200 xg for
10 mins, and resuspended in 20 mL of Isocove’s Modified Dulbeccos Medium (IMDM)
with 2 or 10% FBS, 2 mM L-glutamine, and 100 mg/ml streptomycin and 100 units/ml
penicillin). Cell viabilities and concentrations were then determined using acridine
orange/propidium iodide (AO/PI) staining and a Nexcelom Cellometer Auto 2000
(Manchester, UK).
CFU-E assay
Mouse CFU-E assays was performed according to manufacturer’s instructions
described in detail in version 3.4.0 of STEMCELL Technologies Technical Manual for
Mouse Colony-Forming Unit Assays using MethoCult™. BM cells (4×105 cells) in
IMDM with 2% FBS were transferred into 4 mL MethoCult M3334 methylcellulosebased medium containing EPO (STEMCELL Technologies, Cambridge, MA). Samples
were vortexed thoroughly and transferred in triplicate (1×105 cells) to treated 35 mm

90

culture dishes (STEMCELL Technologies, Cambridge, MA). Samples were incubated for
72 h and CFU-E colonies were enumerated using an inverted microscope. CFU-E colony
counts are reported as number of colonies/million BM cells.
Hematopoietic progenitor cell isolation and in vitro erythropoiesis model
HPC were isolated from BM using the EasySep Mouse HPC Isolation Kit
(STEMCELL Technologies, Cambridge, MA) according to manufacturer’s instructions.
BM cells were concentrated to 1×108 cells/mL in Easy Sep Buffer (DPBS without
calcium and magnesium (DPBS-) containing 2% FBS and 1 mM EDTA) and stained with
a cocktail of biotinylated lineage- specific (CD5, CD11b, CD19, CD45R/B220,
Ly6G/C(Gr-1), TER119) for 15 mins at 4°C. Streptavidin-coated magnetic particles were
added to each sample and incubated for 10 mins. Samples were brought up to 2.5 mL in
EasySep buffer and placed into an EasySep magnet (STEMCELL Technologies) for
isolation. Supernatant containing HPC was collected and utilized to develop an in vitro
model of erythropoiesis as described by Shuga et al., (2007). HPC were cultured in SF
StemSpan hematopoietic progenitor expansion media (STEMCELL Technologies)
supplemented with 100 ng/mL murine SCF and 5 IU/mL (31.25 ng/mL) human
recombinant EPO (Peprotech) to stimulate erythroid lineage commitment and
differentiation.
Flow cytometry
Erythroid and myeloid progenitors were evaluated based on surface marker
phenotype as defined by Pronk et al., (2011) and Grover et al., (2014): PreMegE (Lin-,
cKit+, SCA-1-, CD16/32-, CD150+, CD105-, low); MEP (Lin-, cKit+, SCA-1-, CD16/32-,
CD34-), BFU-E (Lin-, cKit+, SCA-1-, CD16/32-, CD150+, CD105+); CFU-E (Lin-, cKit+,
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SCA-1-, CD16/32-, CD150-, CD105+); pre-Granulocyte Macrophage (pre-GM; Lin-,
cKit+, SCA-1-, CD16/32-, CD150-, CD105-); Granulocyte Macrophage Progenitor (GMP;
Lin-, cKit+, SCA-1-, CD16/32+, CD150-). Erythroblast differentiation was evaluated
based on CD71 and Ter119 surface marker expression and cell size characteristics
subsets (early erythroblasts, CD71low/high, Ter119-,low; EryA, CD71highTer119highFSChigh;
EryB, CD71highTer119highFSClow; EryC, CD71lowTer119highFSChigh) previously described
by Socolovsky et al., (2001) and Koulnis et al., (2011).
For surface marker analysis, 0.5-1×106 cells were stained with 0.5 µg of
monoclonal antibodies (BD Biosciences, San Jose, CA): CD117 clone 2B8 (APC-R700),
CD34 (PE-Cy7), SCA-1 clone D7 (BV605), CD16/32 clone 2.4G2 (BV510), CD150
clone Q38-480 (BV421), CD105 clone MJ7/18 (BB515), CD71 clone C2 (PE) and
Ter119 clone TER-119 (FITC) in 100 µL BD Horizon Brilliant Stain Buffer at room
temperature in the dark for 30 mins. Samples were washed twice and resuspended in 0.5
mL FACS buffer (DPBS- with 2% FBS and 0.09% sodium azide) prior to analysis using a
BD Accuri C6 or BD LSRFortessa flow cytometer.
Immunoprecipitation and co-immunoprecipitation
GATA-1 or PU.1 protein was isolated by immunoprecipitation and GATA1/FOG-1 complex was co-immunoprecipitated as previously described (Zhou et al.,
2011). Briefly, proteins were purified with corresponding antibodies (Cell Signaling
Technologies) using Dynabeads Protein-A Immunoprecipitation Kit (ThermoFisher
Scientific) from cell extracts according to manufacturer’s instructions. To prepare
samples for inductively coupled plasma mass spectrometry (ICP-MS), a non-denaturing
method was used to elute GATA-1 or PU.1 from beads, and the solution adjusted to
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pH>7 using the neutralizing buffer provided in the immunoprecipitation kit.
Inductively coupled plasma-mass spectrometry
Immunoprecipitated GATA-1 or PU.1 protein was collected, and protein content
determined using BCA assay (ThermoFisher Scientific). Protein samples were diluted in
trace metal grade nitric acid, and zinc and arsenic contents in GATA-1 or PU.1 were
measured by ICP-MS. Blank samples, internal standards and standard curves were
included with experimental samples as additional quality control for preparation and
analyses. Results were normalized to immunoprecipitated protein content.
Statistics
Flow cytometry data was processed using FlowJo version 10 software (FlowJo
LLC, Ashland, Oregon). Data were analyzed with GraphPad Prism 7 software.
Differences between untreated control and treatment groups were determined using a
one-way analysis of variance and Tukey's multiple-comparison tests at a significance
level of p<0.05. Three replicates were performed and analyzed for each As+3 dose and at
least three independent experiments were conducted with comparable results attained
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RESULTS

AsIII inhibits erythropoiesis in vivo
To demonstrate the inhibition of erythropoiesis by arsenic exposure through drinking
water, we exposed male C57BL/6J mice to 20, 100, and 500 µg/L AsIII via drinking
water for 30 days. Early erythroid cells (CD71+/Ter119-/low: late BFU-E, CFU-E, and proerythroblasts) were assessed in bone marrow (BM) by CD71 and Ter119 surface marker
expression using flow cytometry (Socolovsky et al., 2011; Koulnis et al., 2011). We
found that AsIII exposure reduced the percentage of early erythroid cells in a dosedependent manner, starting at 20 µg/L (Figure 4.1A). Additionally, to determine if AsIII
compromised the differentiation ability of early erythroid progenitors, we assessed the
colony-forming ability of CFU-E from BM of AsIII exposed mice. CFU-E colony
formation was reduced by AsIII, starting at 20 µg/L and was suppressed over 60% with
the 500 µg/L AsIII dose (Figure 4.1B). These results provide evidence that in vivo
drinking water exposure to environmentally relevant levels of AsIII suppresses the
differentiation of early BM erythroid progenitors.
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Figure 4.1. Inhibition of bone marrow erythropoiesis in vivo by AsIII expsosure. Male
C57BL/6J mice (9 weeks of age) were exposed to 0, 20, 100, and 500 µg/L AsIII in
drinking water for 30 days. (A) Reduction of early erythroid progenitor cells measured by
flow cytometry of CD71 and Ter119 surface markers. (B) Attenuation of bone marrow
CFU-E colony formation (showed as number of colonies/million bone marrow cells). Bar
charts show mean ± SD, n = 5, *, p < 0.05 in one-way ANOVA, Tukey’s multiplecomparison tests compared to untreated group.
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AsIII inhibits erythropoiesis, but not myelopoiesis.
To further demonstrate the inhibitory effect of AsIII on erythropoiesis and
investigate whether AsIII is able to inhibit other hematopoietic pathways, we developed
an in vitro model of erythropoiesis using primary mouse BM HPC stimulated with EPO
and stem cell factor (SCF). The progression of HPC through the stages of hematopoiesis
were assessed based on surface marker phenotype using flow cytometry as previously
described (Pronk and Bryder 2011; Grover et al., 2014). We identified a significant
reduction in the percentage of erythro-megakaryocytic progenitor subsets (MEP, BFU-E,
and CFU-E) after 24 h exposure to 0.5 μM AsIII (Figure 4.2A-B). In contrast, the
percentage of early myeloid progenitors (pre-GM) was significantly increased with
exposure to 0.1 and 0.5 μM AsIII (Figure 4.2C).
These results showed that AsIII inhibition of erythropoiesis starts from very
early stages of differentiation, starting from MEPs. Interestingly, the suppression of
erythroid differentiation introduces a lineage differentiation imbalance, skewing
erythropoiesis in favor of myelopoiesis, despite EPO stimulation and the lack of myeloid
supportive growth factors.
To determine whether the suppressive effects of AsIII on early erythroid
progenitor differentiation persist to later-stages of maturation, we evaluated the
progression of erythroblast differentiation every 24 h for 72 h based on CD71 and Ter119
surface marker expression and cell size (Socolovsky et al., 2011; Koulnis et al., 2011). A
significant suppression of all discernable erythroblast subsets (late BFU-E, CFU-E, and
EryA) was observed after 24 h exposure to 0.5 μM AsIII (Figure 4.2D). These effects
were persistent up to 72 h (Figure 4.2F), with significantly fewer AsIII-exposed

96

erythroblasts properly transitioning to late-stages erythroblast maturation (EryB and
EryC) (Figure 4.2D-F).
Collectively, these results suggest that AsIII inhibits early-stages of erythropoiesis
and these effects are persistent throughout erythroblast differentiation, resulting in
decreased production of mature erythroblasts. However, the suppressive effects of AsIII
were selective to erythro-megakaryocytic progenitors, as myeloid progenitors were not
reduced by AsIII exposure.
To further demonstrate that AsIII selectively inhibits erythropoiesis, we tested the
effects of AsIII on the differentiation of the K562, human erythroleukemia cell line. We
treated K562 cells with 1 μM AsIII for 48 h, during which the cells were induced with
hemin (5 μM) or PMA (5 ng/mL) for 24 h to induce erythroid or megakaryocytic,
myelocytic, and monocytic differentiation, respectively (Villeval et al., 1983; Shelly et
al., 1998; Palma et al., 2012; Huang et al., 2014). In hemin-induced K562 cells, we
measured erythropoietic differentiation using surface marker expression of CD71 by flow
cytometry. AsIII reduced the percentage of erythroid differentiated (CD71+) K562 cells
(Figure 4.3A). Hemoglobin production was also measured as an additional measure of
erythroid differentiation using benzidine staining (Hafner et al., 1995). AsIII treatment at
1 μM significantly reduced the percentage of benzidine positive K562 cells by more than
50% (Figure 4.3B).
Megakaryocytic differentiation of K562 cells was determined using CD41 surface
marker expression by flow cytometry after exposure to 1 μM AsIII. AsIII significantly
reduced the percentage of PMA differentiated megakaryocytic (CD41high) K562 cells
(Figure 4.3C). Further evaluation of forward scatter and CD11b surface marker
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expression, characteristics of myelopoiesis and monopoiesis, showed no significant
differences with AsIII (Figure 4.3D-E). These results showed that in the K562 human
erythroid cell model, AsIII inhibits erythropoiesis and megakaryopoiesis, but not
myelopoiesis or monopoiesis. The selective inhibition of erythroid and megakaryocytic
differentiation and the lack of effects on myelocytic progenitors in two independent cell
models (primary mouse BM and K562 cell line model) motivated us to follow-up with
mechanistic studies focused on understanding the effects of AsIII on the master
regulators of erythropoiesis and myelopoiesis, GATA-1 and PU.1, respectively.
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Figure 4.2. AsIII suppresses erythropoiesis, not myelopoiesis, of primary mouse bone
marrow hematopoietic progenitor cells. Primary mouse bone marrow cells were
stimulated with EPO and SCF for 24 h to promote erythroid differentiation. (A)
Representative flow cytometry plot depicting effects of 0 and 0.5 μM AsIII on erythromegakaryocytic and myeloid progenitor cell subsets. (B) Percentages of surface marker
defined erythro-megakaryocytic progenitors: PreMegE (Lin-, cKit+, SCA-1-, CD16/32-,
CD150+, CD105-, low); MEP (Lin-, cKit+, SCA-1-, CD16/32-, CD34-), BFU-E (Lin-, cKit+,
SCA-1-, CD16/32-, CD150+, CD105+); CFU-E (Lin-, cKit+, SCA-1-, CD16/32-, CD150-,
CD105+) and (C) myeloid progenitors: pre-Granulocyte Macrophage (pre-GM; Lin-,
cKit+, SCA-1-, CD16/32-, CD150-, CD105-); Granulocyte Macrophage Progenitor (GMP;
Lin-, cKit+, SCA-1-, CD16/32+, CD150-) after 24 h exposure to 0, 0.1, and 0.5 μM AsIII.
(D, E, & F) Percentage of erythroblast subsets (early erythroblasts, CD71low/high, Ter119,low
; EryA, CD71highTer119highFSChigh; EryB, CD71highTer119highFSClow; EryC,
CD71lowTer119highFSChigh) after 24, 48, and 72 h exposure to 0, 0.1, and 0.5 μM AsIII.
Data are expressed as mean ± SD, n =3, *, p < 0.05 in one-way ANOVA, Tukey’s
multiple-comparison tests compared to untreated control group.
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Figure 4.3. AsIII disrupts erythroid and megakaryocytic differentiation, not monocyte or
myeloid differentiation of K562 cells. Human K562 erythroleukemia cells were treated
with 1 μM AsIII for 48 h. Erythroid or megakaryocyte, monocyte, and myeloid
differentiation was induced with hemin or PMA for 24 h, respectively. (A) Percentage of
erythropoietic differentiated K562 cells (CD71+) and (B) percentage of benzidine positive
(hemoglobin positive) K562 cells. (C) PMA-induced megakaryocyte differentiation of
K562 cells (CD41high). (D) PMA-induced monocyte (CD11b+ and 2X forward scatter)
and (E) myeloid differentiation CD11bhigh. Data are expressed as mean ± SD, n =3,
*p<0.05 in one-way ANOVA, Tukey’s multiple-comparison tests compared to untreated
control group. Data provided as courtesy of Dr. Xixi Zhou.
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AsIII inhibits GATA-1 activities in vitro
Since erythroid and megakaryocyte differentiation depend on the activity of
GATA-1 (Fujiwara et al., 1996; Shirdasani et al., 1997), we tested the impact of AsIII on
GATA-1 DNA and protein binding. GATA-1 DNA binding activity was determined by
immunoprecipitating GATA-1 from K562 cells or erythroid differentiated mouse BM
HPC and assessing the ability of GATA to bind a GATA consensus sequence using the
EpigentikTM fluorescent protein-DNA interaction kit. In 1 μM and 2 μM AsIII treated
K562 cells, GATA-1 DNA binding activity was dramatically decreased by over 50% and
70%, respectively (Figure 4.4A). GATA-1 DNA binding activity was even more sensitive
in primary mouse BM erythroid cells and an inhibition of GATA-1 DNA binding was
found with 0.1 and 0.5 μM AsIII (30% and 50%, respectively) (Figure 4.4B).
In addition to DNA binding activity, GATA-1 interaction with FOG-1 is also
critical for its function (Tsang et al., 1998). We tested AsIII effects on the interaction
between GATA-1 and FOG-1 using co-immunoprecipitation followed by western
blotting. We found that AsIII treatment in K562 cells significantly inhibited GATA-1 and
FOG-1 interaction, starting from 0.5 μM (Figure 4.4C). At 2 μM concentration, AsIII
reduced the interaction between GATA-1 and FOG-1 by ~75% (Figure 4.4C-D). Since
zinc ion is critical to GATA-1 ZF structure and function, to demonstrate that AsIII
inhibiting GATA-1 is through a zinc dependent mechanism, we used the specific zinc
chelator N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN) to
demonstrate the necessity of zinc to GATA-1/FOG-1 interaction. We found that treating
the K562 cells with TPEN dramatically decreased GATA-1/FOG-1 interaction (Figure
4.4C-D), suggesting that AsIII treatment is equivalent to zinc chelation in terms of
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removing zinc from GATA-1 protein, leading to inhibition of GATA-1/FOG-1
interaction.
Because AsIII treatment caused decreased GATA-1 DNA binding and interaction
with FOG-1, these findings indicate that AsIII disrupts the function of both the N- and Cterminal ZF domains of GATA. Together, our results show that AsIII inhibits GATA-1
DNA binding and protein-protein interaction activities and clearly demonstrate that
GATA-1 is a sensitive molecular target of AsIII.
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Figure 4.4. AsIII impairs DNA binding and FOG-1 interaction activities of GATA-1.
GATA-1 DNA binding was measured using an ELISA DNA binding kit after AsIII
treatment in (A) K562 cells for 48 h and (B) primary mouse bone marrow erythroid cells
after 24 h. (C) GATA-1 and FOG-1 were co-immunoprecipitated from K562 cell lysate
using GATA-1 antibody after AsIII treatments. FOG-1 interaction with GATA-1 after 48
h treatment with 0.5 and 1 μM AsIII. (D) Densitometry of western blotting. Data are
expressed as mean ± SD, n =3, *p<0.05 in one-way ANOVA, Tukey’s multiplecomparison tests compared to untreated control group. Experiment (B) performed in
collaboration with Dr. Xixi Zhou. Data (A,C,D) provided as courtesy of Dr. Xixi Zhou.
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AsIII interacts with GATA-1, not PU.1 through zinc finger disruption.
We demonstrated that AsIII compromises erythropoiesis through the inhibition of
GATA-1 activity (DNA binding and protein-protein interaction) resulting from
impairments of the ZF motifs on GATA-1. To provide further evidence that the AsIIIinduced inhibition of GATA-1 was through ZF disruption, we treated K562 cells and
primary mouse BM erythroid cells with AsIII for 48 and 24 h, respectively. GATA-1 and
PU.1 protein was purified from cell lysates using immunoprecipitation and the Zn and As
contents were measured by ICP-MS. In 1 μM and 2 μM AsIII treated K562 cells, zinc
contents were decreased by over 50% (Figure 4.5A) and arsenic content was dramatically
increased (Figure 5B). GATA-1 from primary mouse BM erythroid cells, showed greater
sensitivity to AsIII (Figure 5D-E). At 0.1 μM and 0.5 μM AsIII concentrations, zinc
contents in GATA-1 were decreased (Figure 5D) and with 0.5 μM were reduced by 50%
(Figure 4.5D). Similar to K562 cells, a dramatic increase in GATA-1 As content was also
found (Figure 4.5E).
These findings indicate that arsenic replaces zinc in GATA-1 ZF motifs. In
contrast, using the same approach, AsIII did not bind to PU.1 in either K562 or primary
mouse BM cells (Figure 4.5C, F), indicating that PU.1 was not a molecular target of
AsIII.
Collectively, these results demonstrated that AsIII binds to GATA-1 ZF motifs,
causing zinc loss, and dysfunction of DNA and protein binding activities (Figure 4.4).
More importantly, the interaction of AsIII with GATA-1 was selective, as no changes to
PU.1 were found.
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Figure 4.5. AsIII binds to GATA-1 causing zinc loss but does not bind to PU.1.
GATA-1 and PU.1 were immunoprecipitated and Zn/As contents were analyzed by ICPMS. (A, B, & C) K562 cells were treated by AsIII for 48 h. (A) Zinc content in GATA-1
from K562 cells treated with 1 and 2 μM AsIII. (B) Arsenic bound to GATA-1 protein in
AsIII treated K562 cells. (C) Arsenic content in PU.1 from AsIII treated K562 cells. (D,
E, & F) Primary mouse bone marrow erythroid cells were treated with 0.1 or 0.5 μM
AsIII for 24 h. (D) Zinc content in GATA-1 from primary mouse bone marrow erythroid
cells. (E) Arsenic bound to GATA-1 from primary mouse bone marrow erythroid cells.
(F) Arsenic content in PU.1 from primary mouse bone marrow erythroid cells. Data are
expressed as mean ± SD, n =3, *p<0.05 in one-way ANOVA, Tukey’s multiplecomparison tests compared to untreated control group. Data from A-C provided as
courtesy of Dr. Xixi Zhou. Experiments (D-F) were performed in collaboration with Dr.
Xixi Zhou.
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AsIII causes GATA-1 zinc finger dysfunction in vivo.
To demonstrate that GATA-1 is a sensitive molecular target of AsIII in vivo, we
tested arsenic binding and zinc loss using GATA-1 protein collected from BM of
C57BL/6J mice exposed to 500 µg/L and 1 mg/L AsIII via drinking water for 2 weeks.
BM cells were isolated from the femurs of each mouse, GATA-1 protein was
immunoprecipitated, and ICP-MS was performed to measure the zinc and arsenic content
in GATA-1. Consistent with findings from our in vitro studies, we found the zinc content
in GATA-1 was significantly decreased with 1 mg/L AsIII (Figure 4.6A). We also found
a dramatic increase of arsenic content in GATA-1 following 1 mg/L AsIII exposure
(Figure 4.6B). These results corroborated our in vitro findings and provided additional
evidence that AsIII interacts with GATA-1 to cause zinc loss and protein dysfunction in
vivo.
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Figure 4.6. AsIII disrupts GATA-1 zinc finger in vivo. Male C57BL/6J mice (12 weeks
of age) were exposed to 500 µg/L and 1 mg/L AsIII in drinking water for 2 weeks. (A)
Zinc content and (B) arsenic content were measured in immunoprecipitated GATA-1 by
ICP-MS. Data are expressed as mean ± SD, n = 6, *p<0.05 in one-way ANOVA, Tukey’s
multiple-comparison tests compared to untreated control group. Experiment performed in
collaboration with Dr. Xixi Zhou.
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DISCUSSION

The lineage commitment and differentiation of HPC is a sophisticated process
regulated by series of factors. Erythropoiesis is largely regulated by the activity of the
key transcription factor, GATA-1 (Fujiwara et al., 1996; Ferreira et al., 2005). GATA-1
binds to the DNA consensus sequences, T/A(GATA)A/G and is responsible for
regulating the expression of a large family of erythropoiesis required genes (Ko and
Engel 1993; Ferreira et al., 2005). Similarly, myelopoiesis is regulated primarily by the
actions of another key transcription factor, PU.1. PU.1 binds to purine-rich DNA
consensus sequences (GAGGAA), and is responsible for activating the expression of
genes required for myelopoiesis and cellular communications in the immune system
(Klemsz et al., 1990; Rhodes et al., 2005; Iwasaki and Akashi 2007). In this study, we
found that AsIII selectively inhibited erythropoiesis, but not myelopoiesis (Figure 4.2,
4.3). This differential inhibition most likely resulted from the structural differences
between GATA-1 and PU.1.
GATA-1 is a ZF protein with two ZF domains, whereas PU.1 is not a ZF protein
without any zinc in the structure. The N-terminal ZF of GATA-1 is responsible for
binding with FOG-1 and the C-terminal ZF is responsible for DNA binding (Ferreira et
al., 2005). Our previous work in DNA repair inhibition by AsIII demonstrated that ZF
proteins such as PARP-1 are sensitive molecular targets of AsIII (Ding et al., 2009). We
found that AsIII selectively interacts with ZF motifs with ≥3 cysteine residues (Zhou et
al., 2011), which are a minority of ZF proteins. Both C- and N-terminal ZFs of GATA-1
contain 4 cysteine residues, making GATA-1 structurally favorable for arsenic binding.
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In contrast, PU.1 contains only two spatially separated cysteine residues and does not
have zinc in its structure. As a result, PU.1 molecule does not interact with and is
insensitive to AsIII.
Our results showed that AsIII exposure not only impaired GATA-1 DNA binding
(Figure 4.4A-B), but also inhibited protein-protein interaction of GATA-1 with the FOG1 (Figure 4.4C-D), indicating that AsIII is capable of binding to both ZFs of the GATA-1
protein. Interaction with FOG-1 and DNA binding are both necessary for the function of
GATA-1 (Tsang et al., 1998; Ferreira et al., 2005); i.e., erythroid lineage commitment
and promotion of erythropoiesis. Previous studies reported that a single germ-line
mutation on just one ZF of GATA-1 leads to dyserythropoietic anemia (Ciovacco et al.,
2008; Del Vecchio et al., 2005). Additionally, a mutation in the N-terminal ZF of GATA1 disrupts DNA binding and results in X-linked thrombocytopenia and b-thalassemia (Yu
et al., 2002). These reports suggest that disruption of either ZF on GATA-1 can cause
dysfunction resulting in hematological disorders. Our results indicate that AsIII impairs
both ZF motifs on GATA-1, which explains why such low concentrations of AsIII may
be able to cause inhibition of erythropoiesis.
The selective interaction of AsIII with GATA-1 ZF vs. PU.1, produced a shift
from erythropoiesis in favor of myelopoiesis (Figure 4.7). The lineage commitment of
CMPs regulated by the functional antagonism of GATA-1 and PU.1 (Zhang et al., 1996;
Rekhtman et al., 1999; Nerlov et al., 2000; Iwasaki and Akashi 2007). Studies have
shown that ectopic expression of GATA-1 or PU.1 block erythroid or myeloid
differentiation, respectively, through the functional repression of gene activation
(Rekhtman et al., 1999; Zhang et al., 1996). The C-terminal ZF of GATA-1 is essential
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for suppressing the function of PU.1 by direct interaction with the ETS domain on PU.1
(Nerlov et al., 2000). The myeloid shift observed in this study (Figure 4.2C) is likely a
consequence of AsIII-induced disruption of the C-terminal ZF of GATA-1. The
hypothesis that AsIII disrupts the lineage commitment of HPC resulting from effects on
lineage specific transcription factors requires further investigation and will be the topic of
our future studies.
In this work, the concentrations of AsIII that produced an inhibition of
erythropoiesis started at 20 µg/L (20 ppb), which is lower than 12% of the AsIII
concentrations measured in water supplies in north central and western regions of the
United States (ATSDR 2007, 2016). Some unregulated water sources in rural areas
around the world contain much higher AsIII concentrations (ATSDR 2007, 2016). Many
regions with high endemic AsIII levels have also been reported to be disproportionately
affected by anemia, even after common risk factors of anemia are considered and
adjusted for (Hopenhayn et al., 2006; Heck et al., 2008; Surdu et al., 2015; Kile et al.,
2016). These studies emphasize the necessity for gaining a mechanistic understanding of
arsenic-caused anemia.
Findings from the present study showed that GATA-1 is a sensitive target of
AsIII. GATA-1 ZF disruption was observed with environmentally relevant concentrations
of AsIII in vitro and in vivo. We identified a clear molecular mechanism by which AsIII
causes GATA-1 ZF disruption that produces effects functionally equivalent to germ-line
mutations of GATA-1. Such mutations of GATA-1 ZF result in severe dyserythropoietic
anemia (Ciovacco et al., 2008; Del Vecchio et al., 2005). Although inherited
dyserythropoietic anemia is rare, millions of people worldwide are chronically exposed to
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AsIII through drinking water. This presents a very important environmental health issue
that requires further attention from the scientific community.
Our work demonstrated for the first time that AsIII, a widespread environmental
toxicant, selectively inhibits erythropoiesis by disruption of the GATA-1 ZF transcription
factor. AsIII selectively interacts with GATA-1 ZF motifs, causing zinc loss and
inhibition of DNA and protein binding activities, resulting in dyserythropoiesis and an
imbalance of HPC differentiation. These findings present a novel mechanism by which
AsIII can cause anemia and provide critical insights into potential prevention and
intervention for arsenic and other environmental exposure related anemias.
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Figure 4.7. AsIII inhibits erythropoiesis, but not myelopoiesis through selective
interactions with the zinc finger transcription factor, GATA-1. AsIII disrupts GATA-1
zinc finger, causing zinc loss and inhibition of DNA/protein binding activities. However,
AsIII does not interact with PU.1, a non-zinc finger transcription factor. The selective
effect of AsIII on GATA-1 vs. PU.1 result in dyserythropoiesis and produce a shift in the
differentiation fate of progenitor cells from erythropoiesis in favor of myelopoiesis.
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KEY POINTS

•

Development of early stage erythroid progenitors was impaired by As+3 and MMA+3.

•

As+3 and MMA+3 disrupt GATA-1 and STAT5 regulated differentiation and survival
of early erythroid cells.

•

MMA+3 is more toxic than As+3 to early developing erythroid cells.
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ABSTRACT

Strong epidemiological evidence demonstrates an association between chronic
arsenic (As) exposure and anemia. However, the underlying mechanisms remain largely
unknown. The goal of this study was to evaluate the effects of arsenite (As+3) and the
As+3 metabolite, monomethyarsonous acid (MMA+3) on two critical regulatory pathways
that control the differentiation and survival of early erythroid progenitor cells. We found
that 500 nM As+3 and 100 and 500 nM MMA+3 suppress erythropoiesis by impairing the
differentiation of early stage erythroid progenitors (BFU-E and CFU-E). The suppression
of early erythroid progenitor development was due to combined effects on differentiation
and survival pathways mediated by disruption of GATA-1 and STAT5. Exposure to 500
nM As+3 and 100 and 500 nM MMA+3 reduced the expression of GATA-1 responsive
genes critical for erythroid differentiation. Additionally, the phosphorylation of STAT5
(pSTAT5) was suppressed by exposure to 100 and 500 nM MMA+3. Impairment of
GATA-1 and pSTAT5 by As+3 and MMA+3 decreased a critical prosurvival factor, Bcl-xL
resulting in the loss of early erythroid progenitors by cell death. Our results show that
As+3 primarily disrupted GATA-1 function; whereas, MMA+3 suppressed GATA-1 and
STAT activation, suggesting that MMA+3 is more toxic than As+3 to early developing
erythroid cells. Collectively, these findings provide novel mechanistic insights into
arsenic-induced dyserythropoiesis.
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INTRODUCTION

Chronic exposure to arsenic (As) in drinking water has been linked to a multitude
of detrimental health outcomes, including cancer, immunosuppression, cardiovascular
disease, neurological disorders, and anemia (Hughes, 2002, Heck et al., 2008, Naujokas
et al., 2013, Tyler and Allan 2014; Ferrario et al., 2016). The primary form of As in
drinking water is the trivalent inorganic arsenical, arsenite (As+3). As+3 is metabolized
through a series of oxidative methylation and reduction reactions catalyzed by the As (+3
oxidation state) methyltransferase enzyme to monomethylarsonic acid (MMA+5),
monomethylarsonous acid (MMA+3), dimethylarsinic acid (DMA+5), and
dimethylarsinous acid (DMA+3) (Thomas et al., 2001, Vahter, 2002). Numerous in vitro
and in vivo studies report MMA+3 to be most toxic arsenical (Styblo et al., 2000; Petrick
et al., 2001). We found that MMA+3 accumulated in the bone marrow of mice exposed to
As+3 in their drinking water for 30 days (Xu et al., 2016b), suggesting that progenitor
cells developing at this site are at an increased risk of MMA+3 exposure and toxicity.
Anemia is a hematological disorder that adversely affects the health of millions of
people worldwide (Koury 2014; WHO 2015). In a cross-sectional study of clinical
indicators of anemia, we found a strong inverse relationship between measures of As
exposure (water and urine) and urinary As metabolites (MMA and DMA) with RBC
counts and hematocrits among a subset of male Health Effects of Arsenic Longitudinal
Study cohort volunteers from rural Bangladesh (Parvez et al., 2017). Other
epidemiological studies also report similar associations between As exposure and anemia
(Hopenhayn et al., 2006, Heck et al., 2008, Surdu et al., 2015, Kile et al., 2016).
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However, the mechanistic basis of such arsenic-induced anemia is not well understood.
Our recent findings show that the development of erythroid progenitors in the bone
marrow is impaired by in vivo and in vitro As+3 exposures (Medina et al., 2017; Zhou et
al., submitted). Therefore, we hypothesize that the inhibition of erythropoiesis may be a
plausible mechanism underlying As-associated anemias.
Red blood cells develop in the bone marrow in response to the hormone,
erythropoietin (EPO). EPO acts on early erythroid progenitors (burst-forming-unit
erythroid (BFU-E) and colony-forming-unit erythroid (CFU-E) to promote survival,
proliferation, and differentiation (Hattangadi et al., 2011; Dzierzak and Philipsen, 2013).
Erythropoiesis is a dynamic and highly regulated process that relies on coordination of
multiple pathways for normal differentiation of erythroid progenitors (Tsiftsoglou et al.,
2009, Hattangadi et al., 2011; Dzierzak and Philipsen, 2013). GATA-1 is an essential
transcriptional regulator of erythropoiesis and is responsible for inducing and repressing
many genes critical for differentiation (Ferreira et al., 2005). Another important
regulatory mechanism in early erythroid progenitors is the EPO-activated Signal
Transducer and Activator of Transcription 5 (STAT5) prosurvival pathway (Socolovsky
et al., 1999; 2001; Liu et al., 2006).
EPO-activated STAT5 signaling utilizes both GATA-1 and STAT5 to regulate
and maintain the expression of the prosurvival factor, B-cell lymphoma-extra-large (BclxL), thereby preventing apoptotic cell death of early erythroid progenitors (Gregory et al.,
1999). Under basal EPO conditions, erythroid progenitors mature to the CFU-E stage, but
most (~60%) succumb to cell death via this mechanism (Wu et al., 1995; Dzierzak and
Philipsen, 2013). During hypoxic conditions, EPO levels are elevated and this prosurvival
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mechanism is fully activated, thereby allowing for the survival and rapid expansion of the
early erythroid progenitor pool (Dzierzak and Philipsen, 2013). This survival mechanism
represents a critical regulatory pathway that directly links EPO levels to the control of
erythropoietic rate by regulating the survival and differentiation of early erythroid
progenitors (Koulnis et al., 2012).
We recently found that As+3 selectively interacts with the zinc finger motifs of
GATA-1 impairing both DNA binding and protein-protein interactions of this critical
transcription factor (Zhou et al., submitted). Additionally, studies from our lab as well as
others have shown that STAT5 phosphorylation is sensitive to As+3 and MMA+3
exposures (Cheng et al., 2004a; Ezeh et al., 2016a; Xu et al., 2016a;). Considering the
importance of GATA-1 function in regulating erythroid differentiation, along with the
importance of this factor in combination with STAT5 for promoting the survival of early
erythroid progenitors, we postulated that these pathways may be responsible for Asinduced suppression of erythropoiesis. In this study, the effects of As+3 and MMA+3 on
GATA-1-regulated differentiation of erythroid progenitors were evaluated. We also
investigated the effects of As+3 and MMA+3 on STAT5 and GATA-1 mediated survival
of early erythroid progenitors.
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METHODS

Chemicals and reagents
Sodium meta-arsenite (NaAsO2, ≥95% purity, CAS 774-46-5, Cat. No. S7400)
was purchased from Sigma Aldrich. Monomethylarsonous acid (CH5AsO2, ≥95% purity,
CAS 25400-23-1, Cat. No. M565100) was purchased from Toronto Research Chemicals
(Toronto, Ontario, Canada). Dulbecco’s phosphate buffered saline w/o Ca+2 or Mg+2
(DPBS-), and Isocove’s Modified Dulbecco’s Medium (IMDM) were purchased from
Sigma-Aldrich (St. Louis, MO). Fetal Bovine Serum (FBS) was purchased from Atlanta
Biologicals (Flowery Branch, GA). Penicillin/Streptomycin 10,000 (mg/ml)/10,000
(U/ml) and 200 mM L-Glutamine were purchased from Life Technologies (Grand Island,
NY). Serum-free (SF) StemSpan medium for expansion of mouse hematopoietic
progenitor cells (Cat. No. 09650) and mouse hematopoietic progenitor cell isolation Kit
(Cat. No. 19856) were purchased from STEMCELL Technologies (Cambridge, MA).
Recombinant murine stem cell factor (SCF) (Cat. No. 250-03) and recombinant human
EPO (Cat. No. 100-64) were purchased from Peprotech (Rocky Hill, NJ). FITC rat antimouse TER119 clone TER-119 (Cat. No. 557915), APC-R700 rat anti-mouse CD117
clone 2B8 (Cat. No565476), BV605 rat anti-mouse SCA-1 clone D7 (Cat. No563288),
BV510 rat anti-mouse CD16/32 clone 2.4G2 (Cat. No. 740111), BV421 rat anti-mouse
CD150 clone Q38-480 (Cat. No. 562811), BB515 rat anti-mouse CD105 clone MJ7/18
(Cat. No. 564744), BD Phosflow™ PE Mouse Anti-Stat5 (pY694) Clone
47/Stat5(pY694) (Cat. No. 612567), BD Horizon™ Brilliant Stain Buffer (Cat. No.
566394), Transcription Factor Buffer Kit (Cat. No. 562574), and Annexin V Apoptosis
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Detection Kit I (Cat No. 556547) were purchased from BD Biosciences (San Jose, CA).
PE GATA-1 (D52H6) XP® rabbit anti-mouse (Cat. No. 13353S) and PE Rabbit (DA1E)
mAb IgG XP® Isotype Control (Cat. No. 5742S) were purchased from Cell Signaling
Technologies (Danvers, MA). AlexaFluor 647 Annexin-V (Cat. No. 640912) was
purchased from Biolegend (San Diego, CA). Acridine orange/propidium iodide (AO/PI)
staining solution in PBS (Cat. No. CS2-0106-5ML) was purchased from Nexcelom
Bioscience (Manchester, UK). RNeasy Mini Kit and QIAshredder were purchased from
Qiagen (Valencia, California). High capacity cDNA reverse transcription kit (Cat. No.
4368814), Gapdh (Mm99999915_g1), Gata-1 (Mm01352636_m1), Gata-2
(Mm00492300_m1), Klf-1 (Mm00516096_m1), EpoR (Mm000833882_m1), Alas2
(Mm00802083_m1), Alad (Mm00476255_m1), Abcb10 (Mm00497926_m1), and Bcl2l1
(Bcl-xL) (Mm01245982_g1) TaqMan gene expression assays, and TaqMan universal
PCR master mix (Cat. No. 4304437) were purchased from Applied Biosystems (Foster
City, CA).
Primary bone marrow cell isolation
All experiments were performed in accordance with protocols approved by the
Institutional Animal Use and Care Committee at the University of New Mexico Health
Sciences Center. Male C57BL/6J mice were purchased at 11 weeks of age from Jackson
Laboratory (Bar Harbor, ME) and allowed to acclimate in our animal facility for one
week. All experiments were performed using male C57BL/6J mice between 12 and 16
weeks of age.
Bone marrow cells from each femur set of three mice were pooled together for all
experiments. Primary mouse bone marrow cells were isolated as previously described
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(Ezeh 2016b). Briefly, bone marrow cells were flushed from both femurs of each mouse
by passing approximately 6-9 mL of media through the marrow shaft using a 1cc syringe
and 25-G needle. The cell suspension was transferred using a 9 in Pasteur pipette to a 15
mL centrifuge tube, centrifuged at 200 xg for 10 mins, and resuspended in 20 mL of
medium IMDM supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, and
100 mg/ml streptomycin and 100 units/ml penicillin). Cell viabilities and concentrations
were then determined using AO/PI staining and a Nexcelom Cellometer® Auto 2000.
Hematopoietic progenitor cell isolation and in vitro erythropoiesis model
Hematopoietic progenitor cells (HPC) were isolated from total bone marrow cells
using the EasySep mouse HPC isolation kit according to manufacturer’s instructions.
Briefly, bone marrow cells were concentrated to 1×108 cells/mL in Easy Sep Buffer
(DPBS- w/ 2% FBS and 1 mM EDTA) and stained with a cocktail of biotinylated lineage
specific antibodies (CD5, CD11b, CD19, CD45R/B220, Ly6G/C(Gr-1), TER119) for 15
mins at 4°C. After 15 mins, streptavidin-coated magnetic particles were added to each
sample and incubated for an additional 10 mins. Samples were brought up to 2.5 mL with
EasySep buffer and placed into the EasySep™ magnet (STEMCELL Technologies,
Cambridge, MA) for 3 mins. After two rounds of isolation, supernatant containing HPC
was utilized to develop an in vitro model of erythropoiesis as described by Shuga et al.
(2007). HPC were cultured in SF StemSpan hematopoietic progenitor expansion media
supplemented with 100 ng/mL murine SCF and 5 IU/mL human recombinant EPO (31.25
ng/mL) to stimulate erythroid lineage commitment and differentiation.
Growth of erythroid progenitor cells was determined based on the concentration
of viable cells after 48 h of erythroid differentiation. The concentration of viable cells in
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was measured using AO/PI staining (20 μL of cells + 20 μL of AO/PI stain) and a
Nexcelom Cellometer.
RNA isolation and quantitative real-time PCR
RNA was isolated from erythroid progenitor cells using the QIAshredder and
RNeasy kit according to manufacturer’s instructions. RNA concentrations were
determined using an Agilent Nanodrop Spectrophotometer. A total of 100 ng of RNA
was utilized for cDNA synthesis using the High Capacity Reverse Transcription Kit.
Samples were diluted 1:4 (v/v) in RNase/DNase free water and stored at -80°C.
Quantitative real-time PCR (qPCR) was performed in 10 µL reactions consisting of
RNase/DNase free water, TaqMan universal PCR master mix, and TaqMan gene
expression assay probes for Gapdh, Gata-1, Gata-2, EpoR, Klf-1, Alas2, Alad, or Bcl-xL
using a BioRad CFX384 Touch Real-Time PCR Detection System (BioRad, Hercules,
CA). The comparative CT method was used for relative quantification of gene expression
using Gapdh as an endogenous control.
Flow cytometry
Early Erythroid progenitor subsets (i.e., BFU-E and CFU-E) were classified as
Lin-, cKit+, SCA-1-, CD16/32-, CD150+,-, CD105+ based on cell surface marker
phenotypes previously described by Pronk and Bryder (2011) and Grover et al., (2014)
(Figure 1A). Late-stages of erythroblast differentiation were measured based on Ter119
surface marker expression as previously described by Socolovsky et al., (2001); Koulnis
(2011) (Figure 1C).
For surface marker analysis, 0.5-1×106 cells were stained with 0.5 µg of
monoclonal antibodies with the following antigen and fluorochrome conjugations:
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CD117 (APC-R700), SCA-1 (BV605), CD16/32 (BV510), CD150 (BV421), CD105
(BB515), Ter119 (FITC) in 50 µL BD Horizon Brilliant Stain Buffer at room temperature
in the dark for 30 mins. Samples were washed twice and resuspended in 0.5 mL
wash/stain buffer (DPBS- with 2% FBS and 0.09% sodium azide) prior to analysis using
a BD Accuri™ C6 flow cytometer or BD LSRFortessa flow cytometer (BD Biosciences,
San Jose, CA).
Intracellular staining was performed using the Transcription Factor buffer kit (BD
Biosciences, San Jose, CA) according to manufacturer’s instructions. Briefly, 0.5-1 x 106
cells were stained with surface markers for 30 mins at 4°C in the dark. Cells were washed
and resuspended in 1 mL of 1X Fixation/Permeabilization reagent and incubated at 4°C
for 45 min. After 45 min, 1 mL of 1X Permeabilization/Wash reagent was added to each
tube and the samples are centrifuged at 350 xg for 6 min. Cells were resuspended in 50
µL BD Horizon Brilliant Stain Buffer containing 0.024 µg GATA-1 (PE) or 20 µL
phosphoSTAT5 (pY694; PE), or concentration, fluorochrome, and isotype matched
controls and incubated at room temperature for 1 h. Cells were washed twice and
resuspended in 0.3 mL wash/stain buffer prior to analysis using a BD LSRFortessa flow
cytometer.
Apoptosis was measured using the BD Annexin-V Apoptosis Detection Kit I
according to manufacturer’s instructions. Briefly, 0.5 x 106 erythroid progenitor cells
were stained with surface markers. After surface marker staining, cells were resuspended
in 100 µL 1X annexin-V binding buffer and stained with 5 µL of AlexaFluor 647
annexin-V and 5 µL propidium iodide for 15 mins at room temperature in the dark. An
additional 400 µL of annexin-V binding buffer and samples were analyzed using a BD

126

LSRFortessa flow cytometer. Erythroid progenitor cells were treated with 5 µM
etoposide for 4 h as a positive control.
Data analysis and statistics
All flow cytometry data was processed using FlowJo version 10 software
(FlowJo LLC, Ashland, Oregon). Data were analyzed with Excel 2010 and Sigma Plot
version 12.5 software. Differences between control and treatment groups were
determined using a one-way analysis of variance (ANOVA) and Dunnett’s t-test at a
significance level of p<0.05. Three replicates were performed and analyzed for each As+3
and MMA+3 dose and at least three independent experiments were conducted, and
comparable results attained.
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RESULTS

As+3 and MMA+3 impair erythroid differentiation of primary mouse bone marrow
hematopoietic progenitor cells
To determine the effects of As+3 and MMA+3 on erythroblast differentiation, we
utilized an in vitro model of erythropoiesis using primary mouse bone marrow HPC
stimulated with EPO and SCF to promote erythroid lineage commitment and
differentiation (Shuga et al., 2007). Utilizing this in vitro model of erythropoiesis, we
assessed erythroblast differentiation based on cell surface marker phenotype using
multiparameter flow cytometry (Pronk and Bryder 2011; Grover et al., 2014) after 48 h
As+3 and MMA+3 exposure (Figure 5.1A).
A significant reduction in the percentage of early erythroid progenitors (i.e., CFUE and BFU-E) was found with 500 nM As+3 (Figure 5.1B). A similar suppression of early
erythroid progenitors was found with MMA+3 at 100 nM; however, early erythroid
differentiation was nearly abolished with 500 nM MMA+3 (Figure 5.1B). Interestingly,
the suppressive effects of As+3 and MMA+3 were selective for erythroid progenitors, as
no significant decreases were observed in other cell lineages (i.e., lymphoid progenitors
and myeloid progenitors; Supplemental Figure 5.S1).
To determine if the reduction of early erythroid progenitors persisted throughout
erythroblast differentiation, we evaluated later-stage erythroblasts based on Ter119 cell
surface marker expression using flow cytometry (Socolovsky et al., 2001; Koulnis 2011)
(Figure 5.1C). Similar to the effects observed on early erythroid progenitors, the
percentage of later-stage erythroblasts (Ter119+) was strongly reduced by 500 nM As+3
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and 100 nM MMA+3, respectively (Figure 5.1D) and very few erythroblasts reached later
stages of erythroblast differentiation with 500 nM MMA+3 (<5% of cells) (Figure 5.1D).
The differentiation of erythroid progenitors is highly dependent on proliferation (Kinross
et al., 2006; Tallack et al., 2007; Pop et al., 2010). As such, we utilized AO/PI staining
and a Nexcelom Cellometer to evaluate cell growth after 48 h exposure to As+3 and
MMA+3. 500 nM As+3 was found to produce a significant suppression of cell growth and
a similar level of inhibition of cell proliferation was seen with 100 nM MMA+3 (Figure
5.1E). MMA+3 at 500 nM inhibited growth to the level of non-EPO and SCF stimulated
HPCs (Figure 5.1E).
Collectively, these results show that As+3 and MMA+3 impair erythropoiesis by
suppressing very early stages of erythroid differentiation. Additionally, both As+3 and
MMA+3 were found to suppress the growth of erythroid progenitors, likely resulting from
the failure to properly differentiate. Our findings also show that MMA+3 produced more
potent suppression of erythropoiesis than As+3.
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Figure 5.1. As+3 and MMA+3 suppress the differentiation and growth of erythroid
progenitor cells. Erythroid differentiation of primary bone marrow hematopoietic
progenitor was induced in vitro with erythropoietin and stem cell factor in the presence of
100 and 500 nM As+3 or MMA+3 for 48 h. Erythroid differentiation was assessed by cell
surface marker phenotype using flow cytometry. (A) Flow cytometry gating strategy used
to define early erythroid cells (BFU-E and CFU-E; cKit+, SCA-1-, CD16/32-, CD150+,-,
CD105+. (B) Percentage of early erythroblasts after treatment with As+3 or MMA+3. (C)
Flow cytometry gating strategy used to define late-stage (Ter119+) erythroblasts. (D)
Percentage of late-stage erythroblasts (Ter119+) following exposure to As+3 or MMA+3.
(E) Erythroid progenitor cell growth measured by acridine orange and propidium iodide
staining using a Nexcelom Cellometer following 48 h exposure to 100 and 500 nM As+3
or MMA+3. Data are expressed as mean ± SD. *Statistically significant difference
compared to control (n = 3; p<0.05).
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Differential suppressive effects of As+3 and MMA+3 on GATA-1 protein and
downstream gene expression in erythroid progenitor cells
We recently showed that the master regulator of erythropoiesis, GATA-1, is a
sensitive molecular target of As+3. As+3 was found to selectively interact with the zinc
finger motifs of GATA-1 disrupting DNA binding and protein-protein interactions (Zhou
et al., submitted). In an effort to determine whether disruption of GATA-1 is responsible
for the suppressed differentiation of early erythroid progenitors, we measured GATA-1
levels in early erythroid progenitors using intracellular flow cytometry and qPCR. We
also assessed the expression of GATA-1-regulated genes important for erythroid
differentiation using qPCR following 24 h As+3 or MMA+3 exposure.
The percentage of GATA-1+ early erythroblasts, the fluorescence intensity of
GATA-1 in early erythroblasts, and Gata-1 mRNA expression were significantly reduced
after 24 h exposure to 100 nM and 500 nM MMA+3 (Figure 5.2A-D). Interestingly, As+3
did not significantly modulate GATA-1 protein in early erythroid progenitors. However,
As+3 did significantly reduce Gata-1 mRNA expression (Figure 5.2A-D). The expression
of several GATA-1-regulated genes critical for erythroid differentiation were
significantly reduced following 500 nM As+3 exposure, including Gata-2, Krüppel-like
factor-1 (Klf-1), and Epo receptor (EpoR) (Figure 5.2D). The effects of MMA+3 on
GATA-1-regulated gene expression were more pronounced. All genes measured (Gata-2,
Klf-1, EpoR, 5- aminolevulinate synthase 2 (Alas2), 5-aminolevulinate dehydratase
(Alad), ATP binding cassette mitochondrial erythroid (Abcb10) were significantly
reduced with 100 and 500 nM MMA+3 (Figure 5.2D).
Taken together, these findings show differential effects of As+3 and MMA+3 on
GATA-1 in early erythroid progenitor cells. Whereas As+3 primarily disrupts GATA-1
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function, MMA+3 disrupts both expression and function of GATA-1, as evidenced by
decreased GATA-1 protein and mRNA levels in early erythroid progenitors as well as
reductions of GATA-1-regulated gene expression.
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Figure 5.2. As+3 and MMA+3 produce differential suppressive effects on GATA-1 protein
and GATA-1-regulated gene expression in erythroid progenitor cells. Erythroid
progenitor cells were treated in vitro with 100 and 500 nM As+3 or MMA+3 for 24 h and
GATA-1 and GATA-1-regulated genes expression was measured in early erythroid
progenitors (BFU-E and CFU-E) by flow cytometry or qPCR, respectively. (A) GATA-1
gating showing isotype control and stained control sample. (B) Percentage of GATA-1+
early erythroid progenitors following 24 h exposure to As+3 or MMA+3. (B) GATA-1
geometric mean fluorescence intensity in early erythroid progenitors. (C) Relative
expression of Gata-1 and GATA-1-regulated genes (normalized to Gapdh) in erythroid
progenitor cells after As+3 or MMA+3 exposure. Data are expressed as mean ± SD.
*Statistically significant difference compared to control (n = 3; p<0.05).
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MMA+3 suppresses STAT5 phosphorylation in early erythroid progenitors
A downstream pathway regulated by GATA-1 in coordination with EPOactivated STAT5 is a critical prosurvival pathway in early erythroid progenitors. As+3 and
MMA+3 have been reported to inhibit the development of early B cells in the bone
marrow and early T cells in the thymus by reducing STAT5 activation (Ezeh et al.,
2016a; Xu et al., 2016a). Since the survival and subsequent maturation of erythroid
progenitors is dependent on STAT5 signaling (Socolovsky et al., 1999; 2001), and taking
into account that this pathway is partially regulated by GATA-1, we hypothesized that the
suppression of early erythroid progenitor cell development may also be influenced by
inhibition of STAT5 signaling.
To determine if As+3 or MMA+3 alter the activation of STAT5, we evaluated the
phosphorylation of STAT5 (pSTAT5) in early erythroid progenitors using
multiparameter intracellular flow cytometry, a method that we have previously validated
by Western Blot (Ezeh et al., 2016a; Xu et al., 2016a). A significant reduction in the
percentage of pSTAT5+ early erythroid progenitors and the fluorescence intensity of
pSTAT5 in early erythroid progenitors was detected following 24 h exposure to 100 and
500 nM MMA+3 (Figure 5.3A-C). A slight reduction of pSTAT5 was also observed with
500 nM As+3; however, it was not statistically significant (Figure 5.3B-C).
These findings show that MMA+3, but not As+3 significantly disrupted the
activation of STAT5 in early erythroid progenitor cells. These findings suggest that;
whereas, As+3 acts dominantly through the inhibition of GATA-1 function, MMA+3
impairs multiple pathways (GATA-1 and pSTAT5) important for erythroid progenitor
differentiation.
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As+3 and MMA+3 impaired GATA-1 and pSTAT5 regulated survival of early
erythroid progenitors
To determine if the suppression of GATA-1 and STAT5 activation resulted in
disruption of STAT5 and GATA-1 regulated survival of early erythroid progenitors, we
measured two downstream factors in the prosurvival pathway (i.e., Bcl-xL and cleaved
caspase-3) using multiparameter intracellular flow cytometry. A significant reduction of
the percentage of Bcl-xL+ erythroid progenitors was found after 24 h exposure to 500 nM
As+3 and 100 and 500 nM MMA+3 (Figure 5.4A-B). Additionally, MMA+3, but not As+3,
significantly decreased Bcl-xL gene expression after 24 h exposure (Figure 5.4C).
Cleaved caspase-3, the terminal factor downstream of Bcl-xL in the STAT5 and
GATA-1 regulated survival pathway, was significantly increased in early erythroid
progenitors treated with 500 nM As+3, and 100 and 500 nM MMA+3 for 24 h (Figure 5AB). In further support of the As+3 and MMA+3-induced impairment of the GATA-1 and
STAT5 mediated survival pathway, we measured cell death using annexin-V and PI
staining in early erythroid progenitors by flow cytometry. At 500 nM As+3 and MMA+3,
there was a reduction of early apoptotic erythroid progenitors in favor of late
apoptosis/necrosis (Figure 5.5C). The percentage of cell death (late apoptosis/necrosis,
annexin-V+, PI+) among early erythroid progenitors was significantly increased by
approximately 2-fold with 500 nM As+3 and 100 nM MMA+3 and approximately 20-fold
with 500 nM MMA+3 (Figure 5.5C-D).
Taken together, these findings provide support that As+3 and MMA+3 impair
GATA-1 and STAT5 regulated survival of early erythroid progenitors, as indicated by
the loss of Bcl-xL, increased caspase-3 activation, and increased death of this population.
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Additionally, as observed in our previous experiments, the effects of MMA+3 on early
erythroid progenitor cell survival were greater compared to As+3.
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Figure 5.3. Effects of As+3 or MMA+3 on STAT5 activation in early erythroid
progenitors. Erythroid progenitor cells were treated in vitro with 100 and 500 nM As+3 or
MMA+3 for 24 h and STAT5 phosphorylation (pY694) (pSTAT5) was measured in early
erythroid progenitors (BFU-E and CFU-E) by flow cytometry. (A) pSTAT5 gating
showing isotype control and stained control sample. (B) Percentage of pSTAT5+ early
erythroid progenitors following exposure to As+3 or MMA+3. (C) pSTAT5 geometric
mean fluorescence intensity in early erythroid progenitors. Data are expressed as mean ±
SD. *Statistically significant difference compared to control (n = 3; p<0.05).
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Figure 5.4. Effects of As+3 or MMA+3 on Bcl-xL in early erythroid progenitors. Erythroid
progenitor cells were treated in vitro with 100 and 500 nM As+3 or MMA+3 for 24 h and
Bcl-xL was measured in early erythroid progenitors (BFU-E and CFU-E) by flow
cytometry. (A) Bcl-xL gating showing isotype control and stained control sample. (B)
Percentage of Bcl-xL+ early erythroid progenitors following treatment with As+3 or
MMA+3. (C) Relative Bcl-xL mRNA expression (normalized to Gapdh) in erythroid
progenitor cells following exposure to As+3 or MMA+3 for 24 h. Data are expressed as
mean ± SD. *Statistically significant difference compared to control (n = 3; p<0.05).
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Figure 5.5. As+3 and MMA+3 increases cleaved caspase-3 and late stage
apoptosis/necrosis of early erythroid progenitors. Erythroid progenitor cells were treated
in vitro with 100 and 500 nM As+3 or MMA+3 for 24 h and cleaved caspase-3 and
apoptosis (annexin-V and propidium iodide (PI) staining) were measured in early
erythroid progenitors (BFU-E and CFU-E) by flow cytometry. (A) Cleaved-caspase 3
gating showing isotype control and 500 nM MMA+3 treated sample. (B) Percentage of
cleaved-caspase 3 in early erythroid progenitor cells following exposure to As+3 or
MMA+3. (C) Apoptosis gating strategy showing representative annexin-V and PI staining
in early erythroid progenitors treated with control (untreated), positive control (5 µM
etoposide), 100 nM As+3, 500 nM As+3, 100 nM MMA+3, or 500 nM MMA+3. (D)
Percentage of early apoptotic erythroid progenitors following 24 h As+3 or MMA+3
treatment. (E) Percentage of late apoptotic/necrotic early erythroid progenitors following
24 h As+3 or MMA+3 treatment. Data are expressed as mean ± SD. *Statistically
significant difference compared to control (n = 3; p<0.05).
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Figure 5.S1. As+3 and MMA+3 do not significantly reduce the percentages of other major
progenitor cell lineages (myeloid and lymphoid). Effects of As+3 and MMA+3 on myeloid
and lymphoid progenitors following in vitro stimulation of primary bone marrow
hematopoietic progenitors with erythropoietin and stem cell factor in the presence of 100
and 500 nM As+3 or MMA+3 for 48 h. Myeloid and lymphoid progenitor differentiation
was assessed by cell surface marker phenotype using flow cytometry as follows: Myeloid
progenitors, pre-granulocyte macrophage (Pre-GM; cKit+, SCA-1-, CD16/32-, CD150-,
CD105-) and granulocyte macrophage progenitor (GMP; cKit+, SCA-1-, CD150-,
CD16/32+) and common lymphoid progenitors (CLP; cKit+, SCA-1int, IL-7Rα+). Data are
expressed as mean ± SD. *Statistically significant difference compared to control (n = 3;
p<0.05).
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DISCUSSION

Erythropoiesis is a dynamic and highly regulated process that requires the
coordination of many molecular regulators for normal development of erythroid
progenitors (Dzierzak and Philipsen, 2013). In this study, we report that As+3 and MMA+3
impair erythropoiesis by disrupting two critical regulatory pathways controlling the
differentiation and survival of early erythroid progenitor cells. As+3 and MMA+3 were
found to suppress GATA-1 regulated erythroid differentiation and impair the GATA-1
and STAT5 regulated survival of early erythroid progenitor cells. We previously reported
that the development of early erythroid progenitor cells is sensitive to As+3 exposure in
vivo and in vitro, likely resulting from functional impairment of GATA-1 (Medina et al.,
2017; Zhou et al., submitted).
In this study, As+3 and MMA+3 produced differential effects on GATA-1. As+3
primarily impaired GATA-1 function; whereas, MMA+3 also impaired GATA-1
regulation, as evidenced by decreased protein expression. As a result, MMA+3 produced
stronger suppressive effects on the expression of erythroid-specific differentiation genes
than equimolar doses of As+3. The decrease of GATA-1-regulated genes with As+3 is
consistent with our previous findings demonstrating that As+3 disrupts the zinc finger
motifs of GATA, thereby inhibiting DNA binding ability and interactions with the
transcriptional coactivator friend of GATA-1 (Zhou et al., submitted).
The functional impairment of GATA-1 caused by As+3 was also evident in this
study, as the expression of GATA-1-regulated genes critical for erythroid differentiation
were significantly reduced. Disruption of GATA-1 function by MMA+3 has not been
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thoroughly evaluated. MMA+3 also disrupts the function of zinc finger proteins (Zhou et
al., 2014), so there is a strong likelihood that it also compromises GATA-1 activity via a
similar inhibitory mechanism as As+3. The interaction of MMA+3 with the zinc finger
motifs of GATA-1 requires further evaluation and will be the topic of our future
investigations. Collectively, the suppression of GATA-1-regulated genes important for
the development of early erythroid progenitors highlights a potential mechanism by
which As+3 and MMA+3 compromise erythropoiesis.
Early erythroid cells are dependent on EPO for survival and differentiation (Wu et
al., 1995; Dzierzak and Philipsen, 2013). The EPO receptor stimulates activation of
STAT5, which in combination with GATA-1, functions to regulate the expression of the
prosurvival factor, Bcl-xL (Gregory et al., 1999). STAT5 knockout studies in mice and
EPO deprivation studies in erythroid progenitor cell models show that loss of STAT5
corresponds to reduced Bcl-xL, increased cell death, and inhibition of erythropoiesis
(Gregory et al., 1999; Silva et al., 1996; Socolovsky et al., 1999, 2001). Similarly,
GATA-1 knockout studies in erythroid progenitor cell models have also demonstrated
that erythroid cells lacking this factor undergo maturation arrest and apoptosis (Weiss et
al., 1994, 1995; Fujiwara et al., 1996).
In this study, we found that As+3 and MMA+3 reduced EPO receptor mRNA
expression, the upstream regulator of STAT5. Additionally, we found that MMA+3, but
not As+3 significantly disrupted STAT5 activation. The suppression of EPO-activated
STAT5 phosphorylation, along with the disruption of GATA-1 expression/function
reduced Bcl-xL in early erythroid progenitors. The loss of Bcl-xL in early erythroid
progenitors resulted in increased activation of caspase-3 mediated cell death. The greater
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cell death response observed with MMA+3, likely resulted from the combined loss of
pSTAT5 and GATA-1 regulation of Bcl-xL.
Several studies have found the phosphorylation of STAT5 is impaired by As+3
and MMA+3 exposure (Cheng et al., 2004a; Ezeh et al., 2016a; Xu et al., 2016a). We
previously reported that As+3 and MMA+3 inhibit the development of pre-B cells in the
bone marrow and pre-T cells in the thymus by reducing STAT5 activation (Ezeh et al.,
2016a). In both of these studies, As+3 had a limited ability to disrupt STAT5
phosphorylation, in comparison with MMA+3 (Ezeh et al., 2016a; Xu et al., 2016a).
Similarly, in the present study, phosphorylation of STAT5 was only significantly reduced
by MMA+3. Considering that the impairment of STAT5 activation has been observed in
two separate progenitor cell lineages (lymphoid and erythroid), it may represent a
common mechanism of As-induced toxicity among HPC.
Our results show that MMA+3 is more toxic than As+3, which is consistent with
many previous in vitro and in vivo studies (Petrick et al., 2001; Stýblo et al., 2000; Ezeh
et al., 2016a; Xu et al., 2017). This is significant because we previously found that the
predominant arsenical in the bone marrow of mice exposed to As+3 in their drinking
water for 30 days was MMA+3, reaching concentrations of approximately 80 nM (Xu et
al., 2016b). Interestingly, there was no detectable As+3 in the bone marrow of these mice
and only minimal levels of other As species (Xu et al., 2016b). As such, when evaluating
As toxicity on bone marrow endpoints, it is important to perform comparative studies
using both As+3 and MMA+3.
In summary, we identified that two important erythropoiesis regulatory pathways
are compromised by As+3 and MMA+3. As+3 and MMA+3 were found to suppress the
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expression of GATA-1-regulated genes important for promoting the differentiation of
early erythroid progenitors. Additionally, As+3 and MMA+3 decreased the Bcl-xLmediated survival of early erythroid progenitor cells through impairments of GATA1/STAT5 and GATA-1, respectively. These findings provide evidence that As disrupts
both differentiation and survival of early erythroid progenitors, resulting in
dyserythropoiesis. Collectively, results from the present study provide novel mechanistic
insights by which As exposures can contribute to the development or exacerbation of
anemia.
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CHAPTER 6

GENERAL DISCUSSION AND SIGNIFICANCE
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GENERAL DISCUSSION

Anemia is a widespread public health issue (WHO 2015). Recent evidence
indicates that the global prevalence of anemia is approximately 33% (Kassebaum et al.,
2014). Many regions with high anemia prevalence are also disproportionately affected by
arsenic contamination (Majumdor et al., 2009; Surdu et al., 2015; Kile et al., 2016). The
high prevalence of anemia in these regions is undoubtedly influenced by socioeconomic
determinants; however, even in the absence of common risk factors of anemia,
associations between chronic arsenic exposure and anemia are still reported (Kile et al.,
2016). Other epidemiological reports also highlight arsenic exposure as an important risk
factor for anemia (Breton et al., 2006; Hopenhayn et al., 2006; Heck et al., 2008;
Majumdor et al., 2009; Surdu et al., 2015; Kile et al., 2016). Despite the clear evidence of
arsenic-associated anemia in chronically exposed human populations, the mechanisms of
arsenic-induced hematotoxicity have not been elucidated.
A major cause of anemia is decreased RBC production in the bone marrow
(Hodges et al., 2007; Gangat and Walanskyj 2013; Koury 2014). Erythropoiesis is a
dynamic, multi-stage process responsible for producing staggering numbers of RBCs to
maintain steady-state physiological conditions (Dzierzak and Philipsen 2013; Kim et al.,
2015a). Although there is a direct correlation between reduced RBC production and
anemia, very few studies have investigated the effects of arsenic on early RBC
development. The present study provides evidence of arsenic-associated anemia in
humans and also demonstrates that this phenotype can be recapitulated in mice following
drinking water exposures to environmentally relevant levels of As+3 (Parvez et al., 2017;
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Medina et al., 2017). For the first time, this work revealed novel mechanistic insights of
how As+3 exposures impair the development of early RBCs, resulting in the inhibition of
erythropoiesis (Zhou et al., submitted; Medina et al., in preparation). Collectively, these
findings suggest that inhibition of erythropoiesis may be a significant contributing factor
to the development and/or exacerbation of anemia in people chronically exposed to
arsenic.
Chronic exposure to arsenic is associated with numerous detrimental health
outcomes (Hughes, 2002; Heck et al., 2008; Naujokas et al., 2013; Tyler and Allan 2014;
Ferrario et al., 2016). However, the hematotoxicity of arsenic is not well understood.
Several studies have shown that arsenic is toxic to mature RBCs in circulation (Winski et
al., 1997; Winski and Carter, 1998; Zhang et al., 2000; Biswas et al., 2008; Mahmud et
al., 2009), but to our knowledge, no studies have been performed to understand the
effects of environmentally relevant arsenic exposures on immature RBCs in the bone
marrow.
In this research, we found that exposure of mice to As+3 at environmentally
relevant levels for 60 days suppressed the development of early erythroid progenitor cells
in the bone marrow (Medina et al., 2017). In contrast to expectations, we did not observe
a decrease in circulating RBC counts in response to the observed reduction of erythroid
progenitors in the bone marrow of As+3 exposed mice. There are two potential
explanations for this outcome, the first is that the terminal time point of the study (60
days) may have been too short to observe systemic effects on RBC levels due to the fact
that the circulating half-life of RBCs in mice is approximately 45 days. Secondly, anemic
conditions, such as those caused by impairment of bone marrow erythropoiesis, induces
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a physiological response mechanism known as stress erythropoiesis to cope with the loss
of RBCs (Socolovsky 2007; Paulson et al., 2011).
An important distinction between mice and humans is that the primary site of
stress erythropoiesis in mice is the spleen; whereas, in humans it occurs predominately in
the bone marrow (Socolovsky 2007; Paulson et al., 2011; Kim et al., 2015b). Although
we did not measure splenic erythropoiesis endpoints in this study, the contribution of
stress erythropoiesis to the lack of RBC decrease cannot be fully excluded and should be
evaluated in future investigations. In our study, it is likely that the As+3-incuded
suppression of bone marrow erythropoiesis resulted in the activation of stress
erythropoiesis in the spleen, thereby producing a compensatory increase in RBC
production. Consistent with this hypothesis, mice in our 60 day As+3 study demonstrated
distinguishing factors of stress erythropoiesis, including elevated circulating EPO levels
and slight trends of increase in total reticulocyte and RBC counts.
Differences in arsenic deposition and exposure provide insights to why
erythropoiesis was compromised in the bone marrow, but likely not the spleen. We
previously found minimal accumulation of arsenic species in the spleen; whereas,
MMA+3 was found to accumulate in the bone marrow (Xu et al., 2016b). Collectively,
results from this study were the first to show that chronic exposure to arsenic in mice
caused anemia and our findings revealed that the differentiation of early erythroid
progenitors is sensitive to in vivo As+3 exposures.
In an effort to elucidate the mechanistic basis for arsenic-induced suppression of
early erythroid differentiation, we developed an in vitro model of erythropoiesis utilizing
primary mouse bone marrow hematopoietic progenitor cells. Utilizing this model system,

149

we found that the suppressive effects of As+3 observed in vivo could be recapitulated in
vitro using this erythropoiesis model. Additionally, we assessed the effects on MMA+3 on
erythroid progenitor cell maturation. As+3 and MMA+3 were found to impair erythroid
differentiation at environmentally relevant and physiologically achievable concentrations,
respectively.
Similar to our in vivo findings, the differentiation of erythroid progenitors was
impaired by in vitro exposures to As+3 and MMA+3, beginning at very early stages of
maturation. Several studies from our lab and others have reported that the differentiation
of lymphoid progenitor cells in the bone marrow is sensitive to low levels of As+3 and
MMA+3 (Ferrario et al., 2008; Ezeh et al., 2014; Ezeh et al., 2016a). Consistent with these
observations, we found that another hematopoietic progenitor cell lineage was also
sensitive to As+3 and MMA+3. However, these findings were the first to show that
exposure to environmentally relevant levels of arsenic disrupts the development of early
RBCs.
Erythroid progenitors are dependent on the activity of a key transcription factor,
GATA-1 (Fujiwara et al., 1996; Ferreira et al., 2005). GATA-1 is a zinc finger protein
containing N- and C-terminal zinc finger domains of the C4 configuration (Ferreira et al.,
2005). Both the N-and C-terminal zinc fingers are critical for the protein-protein
interaction and DNA binding activities of GATA-1, respectively (Fox et al., 1999; Liew
et al., 2005; Bates et al., 2008).
In this project, As+3 was found to interact with GATA-1 causing zinc loss and
functional impairment of both zinc finger motifs of GATA-1 (Zhou et al., submitted).
Previous studies found that zinc finger proteins, such as PARP-1 are sensitive molecular
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targets of arsenic (Ding et al., 2009; Zhou et al., 2011; Sun et al., 2014; Zhou et al.,
2015). Particularly, zinc finger motifs containing ≧3 cysteine residues have been found
to be disrupted by As+3 (Zhou et al., 2011); whereas, MMA+3 is less selective and
interacts with C2H2, C3H1, and C4 zinc fingers (Zhou et al., 2014).
Another important function of GATA-1 is hemoglobin production (Evans et al.,
1988; Pevny et al., 1991; Pevny et al., 1995; Welch et al., 2004; Katsumuara et al., 2013).
Consistent with our findings showing As+3-induced impairment of GATA-1, in our 60day drinking water study, blood hemoglobin levels were decreased in As+3 exposed mice,
which is indicative of hypochromic anemia (Ali 1976). Since hemoglobin production is
largely controlled by the actions of GATA-1, it is likely that the decreased hemoglobin
levels were produced by suppressive effects on GATA-1.
This was the first study to identify that a critical regulator of erythropoiesis, the
zinc finger transcription factor, GATA-1, is impaired by arsenic via the displacement of
zinc, in a similar manner as described for PARP-1 (Zhou et al., 2011). The inhibition of
GATA-1 resulted in dyserythropoieisis, caused by the loss of early erythroid progenitor
differentiation. These findings were the first to identify a mechanism by which arsenic
exposure selectively disrupts the development of RBCs and also provide insights into
potential prevention and intervention strategies for arsenic-associated anemias.
Additionally, these studies revealed that arsenic influenced the lineage
commitment choices of hematopoietic progenitors by selective interference with lineagespecific transcriptional regulators. Functional antagonism between GATA-1 and PU.1
dictates the lineage commitment patterns of early hematopoietic progenitors (Zhang et
al., 1996; Rekhtman et al., 1999; Nerlov et al., 2000; Iwasaki and Akashi 2007). The
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selective effects on GATA-1 vs. a non-zinc finger regulator of myeloid differentiation,
PU.1, disrupted the lineage commitment of hematopoietic progenitors, causing a shift
from erythropoiesis in favor of myelopoiesis.
We previously found that the predominant form of arsenic found in the bone
marrow of mice exposed to As+3 via drinking water for 30 days was MMA+3 (Xu et al.,
2016b). Interestingly, these mice did not have any measurable As+3 and only minimal
levels of other arsenicals (Xu et al., 2016b). Since MMA+3 accumulates in the bone
marrow, it is possible that the effects of As+3 in vivo may be mediated through the
toxicity of MMA+3. In vivo and in vitro studies show that MMA+3 is more toxic than As+3
(Petrick et al., 2001; Thomas et al., 2001; Stýblo et al., 2002). Consistent with these
reports, in this study, MMA+3 was at least 5 times more toxic than As+3 to early
developing erythroid progenitors. In comparison to As+3, MMA+3 has a greater affinity
for interactions with sulfhydryl groups in proteins, exerts greater inhibitory effects on
enzymes, and is more cytotoxic than As+3 (Styblo et al., 1995; Styblo et al., 1997; Lin et
al., 1999; Petrick et al., 2000; Shen et al., 2013). As such, it is likely that MMA+3 disrupts
a broader spectrum of factors important for erythroid development than As+3.
As+3 and MMA+3 were both found to disrupt the development of early erythroid
progenitors through impairment of two critical regulatory pathways mediating
differentiation and survival. Early erythroid progenitors are dependent on GATA-1 for
the induction and repression of many genes critical for normal erythropoiesis (Ferreira et
al., 2005). In addition, GATA-1 functions in cooperation with EPO-activated STAT5 to
control the survival of early erythroid progenitors by promoting the optimal expression of
the prosurvival factor, Bcl-xL (Gregory et al., 1999).
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In this study, As+3 and MMA+3 produced suppressive effects on GATA-1 and the
induction of GATA-1 regulated genes necessary for normal erythroid differentiation,
including the EPO receptor. As+3 primarily alters the function of GATA-1; whereas,
MMA+3 disrupts the regulation and function of GATA-1, and also impairs the EPOinduced activation of STAT5. Previous studies from our lab have found that STAT5
activity is more sensitive to MMA+3 than As+3 exposures in early developing B and T
cells. (Ezeh et al., 2016a; Xu et al., 2016a.). Consistent with previous studies, we also
found that MMA+3 produced stronger suppressive effects on Epo receptor mRNA
expression and STAT5 activation than As+3. The suppressive effects of As+3 and MMA+3
on GATA-1 and GATA-1/EPO-activated STAT5 signaling, respectively, resulted in the
loss of Bcl-xL regulation, causing caspase-3 activation, and death of early erythroid
progenitors.
These findings provide mechanistic support for the arsenic-caused inhibition of
erythropoiesis observed in vivo by identifying that two critical regulatory pathways
important for the differentiation and survival of early erythroid progenitors are disrupted
by As+3 and MMA+3. Loss of differentiation signaling, in combination with the aberrant
death of early erythroid progenitor cells, results in decreased output of mature erythroid
cells, and provides a likely mechanism by which arsenic can cause or contribute to
anemia. Figure 6.1 provides a schematic representation summarizing the effects of As+3
and MMA+3 on early erythroid progenitor cell development.
In summary, this project provided critical insights into arsenic associated anemia
by revealing that environmentally relevant arsenic exposures compromise the
development of early erythroid progenitors in the bone marrow. This project also
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characterized mechanisms responsible for As+3 and MMA+3-induced suppression of
erythropoiesis. Collectively, these findings elucidated novel mechanisms of arsenicinduced hematotoxicity directly relevant to anemia associated with chronic arsenic
exposure. These results provide essential information for understanding the link between
environmental arsenic exposures and anemia.
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Figure 6.1. Summary of As+3 and MMA+3 effects on the development of early erythroid
progenitors (EryP; BFU-E, CFU-E, ProE). As+3 and MMA+3 impair the function of
GATA-1 in MEP and EryP causing a suppression of differentiation. As+3 binds to GATA1 causing zinc loss and dysfunction. MMA+3 disrupts GATA-1 by reducing expression
and activity. The loss of GATA-1 function and expression caused by As+3 and MMA+3,
respectively, also results in an imbalance between GATA-1 and PU.1, thereby shifting
the lineage commitment of CMPs from erythropoiesis in favor of myelopoiesis. MMA+3,
but not As+3 reduces the EPO-induced pSTAT5. Loss of GATA-1 and GATA-1/pSTAT5
caused by As+3 and MMA+3, respectively, reduces the expression of Bcl-xL, resulting in
increased caspase-3 mediated death of early erythroid progenitors. Overall, the disruption
of GATA-1 regulated differentiation and erythroid lineage commitment, combined with
the loss of GATA-1/pSTAT5-mediated survival of early erythroid progenitors, results in
an overall suppression of erythropoiesis. Red and green arrows indicate As+3 or MMA+3
effects, respectively.
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SUMMARY AND SIGNIFICANCE OF AIM 1

Studies in Aim 1 were separated into two components. The first part of Aim 1 was
focused on understanding the association between arsenic exposure and anemia in a
cohort of healthy male volunteers from rural Bangladesh enrolled in the HEALS. The
purpose of our study was to provide additional evidence of the relationship between
arsenic exposure and anemia in men. In this study we found dose-dependent decreases in
RBC counts and hematocrit/packed cell volumes with increasing drinking water arsenic
exposure levels. In an effort to gain an understanding of how arsenic exposures may
interact with other environmental insults, we evaluated the influence of smoking status
and arsenic exposure on clinical indicators of anemia.
These analyses showed that inverse relationships between arsenic exposure and
hematological indicators of anemia were slightly stronger among smokers, indicating
potential interactive effects of smoking and arsenic exposure on anemia. However,
further studies are needed to provide further clarification of these observations.
Collectively, findings from the first part of Aim 1 clearly demonstrated that chronic
drinking water exposure to arsenic was associated with decreases in hematological
indices consistent with clinical manifestations of anemia.
The second part of Aim 1 was focused on determining whether environmentally
relevant As+3 exposure in mice could produce anemia. In these studies, we exposed male
C57BL/6J mice to 0, 100, and 500 ppb As+3 via their drinking water for 60 days. After
the 60-day exposure we evaluated hematological indicators of anemia and also assessed
the development of early erythroid progenitors in the bone marrow using a combination
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of colony forming assays and flow cytometry. We showed for the first time that chronic
drinking water exposure to low-levels of As+3 caused anemia in mice, resulting from a
suppression of early erythroid progenitor cell development in the bone marrow. The
suppression of early erythroid progenitor maturation is consistent with previous studies
from our lab and others that also report the development of hematopoietic progenitors is
sensitive to As+3 and MMA+3-induced toxicity (Ferrario et al., 2008; Ezeh et al., 2014;
Ezeh et al., 2016a).
Collectively, studies from Aim 1 confirmed our hypotheses that arsenic exposure
is associated with indicators of anemia in chronically exposed men and also that exposure
to environmentally relevant levels of As+3 resulted in the development of anemia via
suppression of early erythroid progenitor development in the bone marrow of mice. This
is significant because not only did these findings provide additional epidemiological
evidence of arsenic-associated anemia, but we also showed that anemia could be
recapitulated in a mouse model following exposures to environmentally relevant
concentrations of As+3. These results also identified early erythroid progenitors (i.e., cell
populations directly relevant to anemia) are sensitive to As+3-induced toxicity.
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SUMMARY AND SIGNIFICANCE OF AIM 2

Findings from Aim 1 reveled that early developing erythroid cells in the bone
marrow are sensitive to in vivo As+3 exposures. Studies in Aim 2 were focused on
understanding which specific stages of early erythroid differentiation were impacted by
As+3 and MMA+3 exposure. In these studies, we utilized an in vitro model of
erythropoiesis to assess the effects of As+3 and MMA+3 on the progression of
hematopoietic progenitor cells through the stages of erythropoiesis.
Consistent with in vivo findings from Aim 1, we found that in vitro exposures to
As+3 and MMA+3 in the nanomolar concentration range, suppressed the development of
erythroid progenitors starting from very early stages of differentiation. The compromised
differentiation of these early erythroid progenitors (i.e., MEP, BFU-E, CFU-E) persisted
throughout erythropoiesis, resulting in significantly fewer erythroid progenitors reaching
late stages of maturation. These studies confirmed our observations from Aim 1 that early
erythroid progenitor subsets were disrupted by As+3 and MMA+3 exposures and provided
additional information on the specific subsets impacted by arsenic exposure.
These findings also showed that MMA+3 produced suppressive effects to early
erythroid progenitor differentiation that were at least 5 times greater than As+3. This is
significant because we recently found that the predominant species of arsenic that
accumulates in the bone marrow of mice exposed to As+3 in vivo is MMA+3 (Xu et al.
2016b). This suggests that the suppressive effects on early erythroid differentiation
observed in Aim 1 may be significantly mediated by MMA+3-induced toxicity.
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Overall, findings from these studies confirmed our hypothesis that As+3 and
MMA+3 suppress the in vitro differentiation of primary mouse bone marrow erythroid
progenitors. Our results clearly identified early erythroid progenitors as sensitive targets
of As+3- and MMA+3-induced toxicity and also revealed differential sensitivities of these
cells to As+3 and MMA+3.
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SUMMARY AND SIGNIFICANCE OF AIM 3

The development of early erythroid progenitors is dependent on the activity of the
zinc finger transcription factor GATA-1 (Fujiwara et al., 1996; Ferreira et al., 2005).
GATA-1 is responsible for orchestrating the expression of a wide range of erythroid
specific genes critical for normal erythropoiesis. Additionally, in early erythroid
progenitors, GATA-1 functions in cooperation with EPO-activated STAT5 to promote
survival and differentiation (Gregory et al., 1999). Zinc finger proteins and STAT5
activation have been reported as targets of As+3 and MMA+3 toxicity (Cheng et al.,
2004a; Ding et al., 2009; Zhou et al., 2011; Sun et al., 2014; Zhou et al., 2015; Ezeh et
al., 2016a, Xu et al., 2016a).
Aims 1 and 2 demonstrated that early erythroid progenitors are sensitive to As+3
and MMA+3 exposures in vivo and in vitro, respectively. The development of early
erythroid progenitor cells is dependent on the activities of GATA-1 and STAT5.
Therefore, in Aim 3 we evaluated the hypothesis that As+3 and MMA+3 suppress the
development of early erythroid progenitors by combined effects on differentiation and
survival, caused by impairments of GATA-1 and EPO-activated STAT5 signaling.
Utilizing a combination of in vivo and in vitro studies, we found that As+3
selectively interacts with GATA-1, causing zinc loss, and inhibition of DNA and proteinprotein binding activities. The loss of GATA-1 function resulted in dyserythropoiesis and
an imbalance of hematopoietic differentiation. This was the first study to demonstrate
that an essential regulator of erythropoiesis, is selectively impaired by As+3 exposure
through zinc finger disruption. The inhibition of GATA-1 produced by As+3 was
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independent of changes in expression, as no changes in GATA-1 protein levels were
found in early erythroid progenitors. Follow up studies revealed that the loss of GATA-1
function reduced the expression of GATA-1 responsive genes critical for the
differentiation of early erythroid progenitor cells.
In contrast to As+3, MMA+3 disrupted the expression and function of GATA-1.
Additionally, MMA+3, but not As+3, reduced the EPO-induced activation of STAT5. Loss
of GATA-1 and GATA-1/STAT5 compromised the regulation of Bcl-xL, which resulted
in increased caspase-3-mediated death of early erythroid progenitors. This is significant
because it demonstrated for the first time that As+3 and MMA+3 disrupt two critical
regulatory pathways in early erythroid progenitors that control differentiation and
survival. Collectively, As+3- and MMA+3-mediated effects on GATA-1 result in fewer
cells differentiating to the erythroid lineage and cells that do differentiate to early stages
of erythropoiesis are susceptible to death resulting from the loss of GATA-1 and STAT5
mediated survival. This presents a novel mechanism of arsenic-induced suppression of
erythropoiesis.
These studies confirmed our hypothesis that As+3 and MMA+3 impair early
erythroid progenitor development by combined effects on differentiation and survival
signaling pathways. These findings were the first to clearly demonstrate a mechanistic
basis of arsenic-induced suppression of early erythroid progenitor development. Taken
together, these findings suggest that dysregulation of erythropoiesis is a probable
mechanism of anemia in people chronically exposed to arsenic.
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OVERALL SIGNIFICANCE

This is the first comprehensive study assessing the underlying mechanisms of
arsenic-associated anemia reported in human populations chronically exposed to arsenic
(Brenton et al., 2006; Hopenhayn et al., 2006; Heck et al., 2008; Majumdor et al., 2009;
Surdu et al., 2015; Kile et al., 2016). In this study, we show a relationship between
arsenic exposure and anemia in humans and this effect was recapitulated in mice, clearly
establishing the role of arsenic exposure in the development of anemia. We report for the
first time, that early stages of erythroid progenitor development are sensitive to arsenicinduced toxicity. This study also identified mechanisms of arsenic-induced suppression
of erythropoiesis. These are the first findings to show that arsenic exposure compromises
the function of the master regulatory factor of erythropoiesis, GATA-1.
Selective interaction of As+3 with the zinc finger motifs of GATA-1 was
identified as a mechanism of As+3-induced suppression of early erythroid progenitor
differentiation. Not only did we identify that direct effects of As+3 on GATA-1
compromised the differentiation of early erythroid progenitors, but we also found that
loss of GATA-1 impaired the regulation of a critical prosurvival factor, Bcl-xL resulting
in aberrant death of the early erythroid progenitor cell pool. This is the first report to link
As+3 exposure to a molecular mechanism of impaired erythropoiesis, which is directly
relevant for understanding the basis of anemia and other hematological disorders in
human populations chronically exposed to arsenic.
Additionally, this was the first study to evaluate the effects of MMA+3 on
erythroid progenitor development, which is significant because our studies revealed an
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inverse association between urinary MMA and RBC counts in a cohort of men from rural
Bangladesh (Parvez et al., 2017), highlighting the importance of arsenic metabolism in
arsenic-associated anemias. People with variants of As3MT that reduce As+3 methylation
capacity may be at an elevated risk of anemia resulting from MMA+3-induced
suppression of erythropoiesis. Our previous studies indicate that MMA+3 is the
predominant form of arsenic in the bone marrow following in vivo As+3 exposures in
mice (Xu et al., 2016b), suggesting that cells at this site are at an increased risk of
MMA+3 exposure and toxicity. This study revealed for the first time that early stages of
erythroid progenitor differentiation are more sensitive to MMA+3 than As+3 and also
provided mechanistic information for the observed differences in toxicity.
MMA+3 produced differential effects on GATA-1 by reducing regulation and
function, as indicated by decreased protein levels and by the suppression of GATA-1
responsive gene expression, respectively. In contrast to As+3, MMA+3 also disrupted
STAT5 activation. Similar to As+3, but at concentrations 5 times lower, we found MMA+3
also disrupted GATA-1 regulated differentiation and caused a substantial loss of early
erythroid progenitors by cell death resulting from the combined loss of GATA-1 and
EPO-activated STAT5 regulation of Bcl-xL. Inhibition of STAT5 activation has been
reported in other progenitor lineages following MMA+3 exposure (Ezeh et al., 2016a; Xu
et al., 2016a), and therefore, may represent a common mechanism of MMA+3 toxicity to
hematopoietic progenitor cells.
For the first time, this study provides mechanistic evidence of arsenic-induced
suppression of early erythroid progenitor development. Selective suppression of
erythropoiesis by arsenic is a probable means by which environmental arsenic exposures
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cause anemia or exacerbate existing anemia. Dysregulation of erythropoiesis is a
potential mechanism underlying the high prevalence of anemia in people chronically
exposed to arsenic. Findings of this project not only elucidated a mechanistic basis of
arsenic-associated anemia, but also provide critical information for developing prevention
and intervention strategies for arsenic and potentially other environmental metal exposure
related anemias and hematological disorders.
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FUTURE DIRECTIONS

The present study provided novel mechanistic insights into arsenic-induced
suppression of erythropoiesis, which may be an underlying factor in arsenic associated
anemias. However, the following questions should be addressed in future studies to
provide further support for this phenomenon:
•

Is the toxicity of As+3 and MMA+3 to early developing erythroid progenitors the
same in males and females? The present study only focused on understanding the
effects of As+3 and MMA+3 on erythropoiesis in males, therefore whether RBC
development in females is impacted to the same extent and through the same
mechanisms remains to be explored. This is a very important consideration, because
many epidemiological studies have identified women as having a high risk of arsenicassociated anemia (Brenton et al., 2006; Hopenhayn et al., 2006; Heck et al., 2008;
Majumdor et al., 2009; Surdu et al., 2015; Kile et al., 2016). To gain this
understanding, the following hypothesis should be addressed: As+3 and MMA+3
suppress the development of early erythroid progenitors by combined effects on
differentiation and survival caused by impairments of GATA-1 and EPO-activated
STAT5 signaling in females. To test this hypothesis, a series of experiments similar
to those performed in Aims 1-3 of this study can be performed.

•

In the absence of erythropoietic contributions from the spleen, is loss of bone
marrow erythropoiesis caused by arsenic sufficient to produce anemia in a mouse
model? Since the primary erythropoietic and stress erythropoietic organ in humans is
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the bone marrow (Socolovsky 2007; Paulson et al., 2011; Dzierzak and Philipsen
2013; Kim et al., 2015b), these studies would provide information more reflective of
environmental arsenic exposures in human populations. Findings from the present
study show that arsenic impairs bone marrow erythropoiesis; however, further in vivo
studies are required to provide direct evidence that compromised bone marrow
erythropoiesis is responsible for anemia development. This can be determined by
exposing splenectomized (or sham control) male and female mice to As+3 at
environmentally relevant levels in their drinking water for 90 days (twice the half-life
of circulating RBCs) and inducing anemia by periodic bleeding (Moreau et al., 2012)
or iron deficiency (Asperti et al., 2018). This would test the hypothesis that As+3induced inhibition of bone marrow erythropoiesis impairs the ability to recover from
anemia, which in the absence of splenic contributions, would be dependent on the
bone marrow.
•

Is there a relationship between arsenic exposure, iron deficiency, and anemia?
The vast majority of anemia worldwide is resultant of iron deficiency (WHO 2015),
and many of the regions most affected by this type of anemia are also areas with high
endemic arsenic exposures. Many of the aforementioned epidemiological studies of
anemia in arsenic exposed women show exacerbations during pregnancy, suggesting
potential interactive effects between arsenic exposure and pregnancy-related anemia,
which is generally caused by iron deficiency (McMahon 2010). As such, it is
important to understand whether arsenic exposures influence the severity of anemia in
instances of iron deficiency. To address this, the following hypothesis should be
tested: Iron deficiency anemia is exacerbated in males and females by
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environmentally relevant exposures to As+3. To test this hypothesis, the relationship
between the presence of anemia and anemia severity can be determined in iron
deficient men and women who are chronically exposed to arsenic. Many
epidemiological cohorts, such those in rural Bangladesh, are in regions
disproportionately affected by iron deficiency anemia (Ahmed 2000; Jamil et al.,
2008) and could serve as ideal populations to understand the association between iron
deficiency, chronic arsenic exposure, and anemia. Additionally, iron deficiency
anemia is a common comorbidity among heart failure patients (Anand and Gupta
2018). As such, heart failure patients who have chronic arsenic exposures may also be
good population for these studies.
Experiments can also be performed in the laboratory using in vivo mouse
models. Male and female mice can be exposed to environmentally relevant levels of
As+3 via drinking water and iron deficiency anemia can be simultaneously induced by
feeding iron deficient chow. Anemia can be measured in unexposed and As+3 exposed
mice based on hematological parameters. The development of RBCs can also be
assessed using a combination of flow cytometry and colony forming assays. Pending
the outcomes of these investigations more detailed follow-up hypotheses can be
generated using in vitro and in vivo mouse models to better understand the
mechanisms of these effects.
•

Does MMA+3 disrupt cell cycle regulation in early erythroid progenitor cells? In
early erythroid cells, KLF-1 expression is regulated by GATA-1. In this study we
found that As+3 and MMA+3 disrupt GATA-1, resulting in decreased Klf-1 mRNA
expression (Figure 6.2A). KLF-1 regulates the activation of E2F2, which promotes
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cell cycle entry (i.e., transition to S phase) and subsequent differentiation of early
erythroid progenitor cells (Tallack et al., 2007, 2009; Pilon et al., 2008). Loss of
KLF-1 and subsequent E2F2 regulation results in an accumulation of early cKit+
progenitors that fail to undergo erythroid differentiation due to failure of successful
cell cycle entry (Tallack et al., 2007, 2009; Pilon et al., 2008; Gnanapragasan et al.,
2016). MMA+3 at 100 and 500 nM reduced E2f2 mRNA expression in erythroid
differentiated hematopoietic progenitor cells (HPC) after 24 h exposure (Figure 6.2B)
and caused an increase in cKit+, SCA-1- progenitors (Figure 6.2C). This suggests that
the accumulation of HPC may be caused by the loss of E2F2-mediated cell cycle
entry and failure to subsequently undergo erythroid differentiation.
These preliminary findings provide support for the following hypothesis:
MMA+3 disrupts KLF-1 (possibly through the impairment of GATA-1), resulting in
loss of E2F2 mediated cell cycle entry and failure of HPC to undergo erythropoiesis.
This hypothesis can be tested using a combination of in vitro and in vivo mouse
studies. Using the in vitro erythropoiesis model outlined in this study, erythroid
progenitors can be exposed to MMA+3 at 0, 100, and 500 nM and the effects on cell
cycle and cell cycle regulators (e.g., cyclins, cyclin dependent kinases, cyclin
dependent kinase inhibitors) can be measured by flow cytometry. Additionally,
effects on KLF-1 and E2F2 as well as on cell cycle and cell cycle regulators can be
measured in early bone marrow erythroid progenitors following in vivo exposures of
male and female mice to environmentally relevant levels of As+3.
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Figure 6.2. Effects of As+3 or MMA+3 on KLf-1 and E2f2 mRNA expression and cKit+,
SCA-1- progenitors. Hematopoietic progenitor cells were treated in vitro with 100 and
500 nM As+3 or MMA+3 for 48 h and Klf-1 and E2f2 mRNA expression was measured by
quantitative real-time PCR. The percentage of cKit+, SCA-1- progenitors was assessed by
flow cytometry. (A) Klf-1 and (B) E2f2 mRNA expression (normalized to Gapdh)
following exposure to As+3 or MMA+3. (C) Percentage of cKit+, SCA-1- progenitors
following treatment with As+3 or MMA+3. Data are expressed as mean ± SD.
*Statistically significant difference compared to control (n = 3; p<0.05).
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